

Index

- abatacept, 426
abscesses, 230, 476, 482, 627
 abdominal, 3
 amebic, 649
 appendiceal, 233
 in CD, 236
 crypt, 294, 604
 epidural, 238
 hepatic, 544
 perianal, 236, 491
 perirectal, 236
 pre-sacral, 238
 psoas, 236, 482
 pyogenic, 41
 splenic, 648
Academy of Managed Care Pharmacy, 310
acarbose, 602
ACCENT trials, 371, 386, 473, 475, 477
acetic acid, 167
acetylation, 86, 87
acetylcholines, 167, 184, 611
N-acetylglucosamine (N-AG), 593
N-acetylsulfapyridine, 419
acne, corticosteroid-induced, 565
acquired immunodeficiency syndrome (AIDS) *see*
 HIV/AIDS
actin, 646–7
α-actinin, 646
Actinobacteria, 95
active comparator, vs. Placebo, 324
activity index *see* Crohn's disease activity index
 (CDAI); perianal disease activity index
 (PDAI); pouchitis disease activity index
 (PDAI); ulcerative colitis activity indices
acupuncture, 698
 mode of action, 699–700
Acute Ulcerative Colitis Trials (ACT 1 & 2), 371
Adacolumn apheresis, 428–9
adalimumab, 130, 188, 204, 310–11, 374–5,
 425
 and arthritis, 558
 and CD, 472–3, 475, 477–8
 costs of, 386
 efficacy and safety, 374
 and gastrointestinal complications, 385
 and heart failure, 384
 and malignancy, 385
 mechanism of action of, 374
 medico-legal issues, 708–9
 and multiple sclerosis, 684
 and neurologic events, 385
 in pediatric patients, 590
 pharmacokinetics of, 374–5
 and pregnancy, 576–7
 and pyoderma gangrenosum, 565
 safety issues, 678, 681, 683
 and tuberculosis, 383, 683
adenitis, mesenteric, 295
adenocarcinomas, 29, 38, 222, 230, 256
 colorectal, 520–1, 614
adenoma-like lesions or masses (ALMs), 247, 252
adenomas, 174, 247, 263
 sporadic, 520–1
adenosine, 611
adenovirus, 139
ADHERE study, 475
adhesion, inhibitors of, 379–82
adhesion molecules, 133, 160, 163, 187, 532
 downregulation of, 346
adipocytokines, 205
adiponectin, 205
adipose tissue, 347
adrenal corticotrophin hormone (ACTH), 422
adrenal gland, 347
Adverse Event Reporting System (AERS), 678
Aeromonas, 292, 294, 296, 649, 654
age, at diagnosis of IBD, 520
Alagille syndrome, 575
alanine, 258
alendronate, 541
 and pregnancy, 574
alicaforfen, 381–2, 425, 463
allergens, contact, 32
allopurinol, 428
Aloe vera, 409, 429
 gel, 695, 699, 709
alopecia, 42
alternative medicine *see* complementary and
 alternative medicine (CAM)
amebae, 246–7, 295
amebapore, 646
amebiasis, 292, 295–6, 644–5, 651–3
amebomata, 652
American Academy of Pediatrics, 573
American College of Gastroenterology (ACG),
 312, 637, 710
American Gastroenterological Association (AGA),
 589, 710
 Technical Review on Osteoporosis, 669
American Society of Colon and Rectal Surgeons,
 312
American Society for Gastrointestinal Endoscopy,
 257, 710
American Thoracic Society (ATS), 684
aminoglycosides, 394, 433
 parenteral, 623
4-aminoquinolones, 429
4-aminosalicylate, 427
 para-aminosalicylate (PAS), 427
5-aminosalicylates, 237, 239, 256, 360, 417–20, 432,
 463
 and arthritis, 558
 and CRC, 521–2
 and cuffitis, 464
 formulations, 416
 medico-legal issues, 707
 in pediatric patients, 587–8
 and postoperative recurrence, 501–2, 502
 and pregnancy, 572
 see also balsalazide; olsalazine; sulfasalazine
5-aminosalicylic acid (5-ASA), 221, 255, 287, 346,
 348, 419–20, 501, 509, 610, 695
 in pediatric patients, 587–8
 see also mesalamine; mesalazine
amoxicillin
 and *C. difficile* diarrhea, 622
 and pouchitis, 462
 and pregnancy, 573
amoxicillin-clavulanate, 622
amphiregulin, 171
ampicillin, and *C. difficile* diarrhea, 622
ampulla of Vater, 256
amylase, 238
amyloidosis, 42, 237, 604
 hepatic, 543
 and IBD, 204–5
 secondary, 197
anakinra, 133
anal anastomosis, 4
anal canal, lesions of, 491
anal dilation, 491
anal inflammation, 31
anal sphincter, 184, 268, 572
anal transitional zone (ATZ), 448, 450, 458, 463–4
analgesics
 in arthritis, 558
 narcotic, 632
anaphylaxis, 198–9, 382, 646
anastomosis, 490
 double-stapled, 450
 hand-sewn, 450
 and recurrence rates, 486
anechoic solution, 267
anemia, 38, 197–199, 293, 649
 aplastic, 199
 of chronic disease (ACD), 197–8

716 Index

- anemia (*Cont.*)
 hemolytic, 39–40, 199–200, 648
 in IBD, 409
 evaluation of, **200**
 iron deficiency, 183, 197–8, 293, 587
 megaloblastic, 198–9
 microcytic, 586
 pernicious, 645
 anergy, clonal, 59
 aneuploidy, 509, 511, 514
 and dysplasia, 511
 angiogenesis, 157, 158, 167, 609, 613
 and IBD, 161–2
 angiogenic mediators, in IBD and colitis, 162–3
 angiotensin II, in inflammation, 166–7
 angiotensin-converting enzyme (ACE), 611
 animal models, 25
 of colitis, 164
 and IBD heterogeneity, 7
 see also mice; rats
 anismus, 464
 ankylosing spondylitis, 36, 554
 annexin V, 373
 anorexia, 195–6, 229–30, 591, 593
 nervosa, 595
 anti-peristaltic agents, 632
 anti-platelet activating factor agents, 426
 anti-TNF agents *see* antibodies, anti-TNF α ;
 infliximab
 antibiotics, 392–401, 427–8, 616, 632, 650, 653
 associated diarrhea (AAD), 627
 broad spectrum, 183, 645
 and *C. difficile* diarrhea, 622, 635–6
 clinical trials of, **394–6**
 and microscopic colitis, 606
 in pediatric patients, 590
 and postoperative recurrence, 503
 and pregnancy, 572–3
 and PSC, 539
 and SCAD, 615
 antibodies
 ABT-874, 377
 ACCA, 280–1
 ALCA, 280–1
 anti-cardiolipin, 201
 anti-CBir1, 6, 72, 236, 280–4
 anti-glycan, 280–1
 anti-I2, 5–6, 72, 236, 282–3
 anti-IFN- γ , 126
 anti-IL6R, 376
 anti-IL12p40, 121
 anti-Mac1, 121
 anti-*Saccharomyces cerevisiae* (ASCA), 5–6, 72,
 236, 251, 279–84, 462, 586–7
 anti-TNF α , 82, 130, 424–5, 590, 681–2
 side effects of, **682**
 see also infliximab
 antigliadin, 602
 antinuclear (ANA), 383
 atypical anti-neutrophil (ANCA), 532
 cANCA, 279, 532
 and CD, 236–7, 280
 chimeric, 366
 human, 366
 anti-chimeric (HACAs), 424–5
 humanized, 366
 see also adalimumab
 IgA, 280, 282–3
 IgG, 280, 282–3, 363, 624, 636
 isotypes of, 363
 monoclonal (mAbs), 362–7, 424–5
 antibodies to, 382–3
 BG9588, 379
 CDP571, 425, 590
 ch5D12, 379
 cM-T412, 379
 general structural features of, 362–3, 364
 IDEC-131, 379
 mechanism of action of, 366
 MLN-02, 381, 425
 muromonab (OKT3), 364, 366, 379
 pharmacokinetics of, 367
 production of, 363–6, 365
 routes of administration of, 367
 outer-membrane porin C (anti-OmpC), 5–6, 72,
 236, 280–3
 perinuclear anti-neutrophil (pANCA), 5–6, 39,
 236, 279–84, 461–2, 532–3, 586–7
 regions of, 266–7
 STA-5326, 377
 to infliximab (ATI), 382, 424–5
 antibody-dependent cell-mediated cytotoxicity
 (ADCC), 366
 anticholinergics, 433
 anticoagulant pathways, 165
 antidepressants, 433
 tricyclic, 189, 465
 antidiarrheals, 465
 narcotic, 433
 antigen receptors, 102
 antigen-presenting cells (APCs), 54, 65, 97, 121
 IECs as, 101–4
 antigens, 97
 access to LPL compartment by, 99
 bacterial, 103, 713–14
 common leukocyte (CLA), 603
 CTLA-4, 60
 enteric, transport of, 159
 in food, 93, 103
 LFA-1, 381
 luminal, 361
 presentation of, 101–4
 to T cells, 186–7
 processing in intestine, 53
 self, 557
 sialyl-Tn (STn), 514
 antimicrobial agents, and *C. difficile* diarrhea,
 622
 antioxidants, 405
 antiphospholipid antibody syndrome, 577
 antispasmodics, 465
 antithrombin, 164, 201
 anus, 217
 anxiety, 238
 APC 2059, 429
 apheresis, 428–9
 apoptosis, 40, 84, 130, 173, 183, 350
 and adalimumab, 374
 and IL-2, 58
 and infliximab, 373–4
 neutrophil, 133
 resistance, 85
 appendectomy, 217–18
 appendicitis, 648
 balantidial, 649
 and HIV, 661
 appendix, 104
 and CD, 233
 in IBD, 249
 inflammation of orifice, 218
 arachidonic acid, 592
 arc of Riolan, 610
Aristolochia, 701
Artemisia absinthium, 697
 arteries
 anastomotic, 610
 colic, 610
 of Drummond, 610
 iliac, 610
 inferior mesenteric (IMA), 610
 rectal, 610
 sigmoid, 610
 superior mesenteric (SMA), 449, 610
 arterioles, 167, 610–12
 arthralgias, 195, 198, 553, 557
 arthritis, 34, 36, 223, 648
 analgesia in, 558
 axial, 554–5
 diagnosis, 557
 treatment, 558
 clinical features of, 557
 colitic, 230
 and environmental factors, 555–7
 and IBD, 553–4
 juvenile idiopathic, 376
 management of, 557–9
 pathogenesis of, 554–5
 peripheral, 554–5, 555
 diagnosis of, 557
 treatment of, 558–9
 Type 1 (pauciarticular), 553–6, 558–9
 Type 2 (polyarticular), 553–5, 557, 559
 post-infection, 557
 psoriatic, 554
 reactive, 554–5, 648
 rheumatoid, 133–4, 197, 203, 205, 310–11, 339,
 376, 477, 681
 septic, 557, 627, 648
 Asacol, 417, 419–20, 473, 501–2
 see also mesalazine
 ascites, 542, 628–9
 ascorbic acid, 409
 aspartate aminotransferase, 258
 aspergillosis, 384, 424, 684
 aspirin, 602, 616
 and sporadic CRC, 508
 asthma, 44, 137, 299, 339
 ASTIC trial, 478
 atherosclerosis, 74
 ATN-161, 163–4
 atopy, 44
 Atripla, 659
 atrophy, thymic, 126
 atropine, 632
 Augmentin, 622

- autoantibodies, 35, 533
 - pancreatic (PAB), 238
- autoimmune disease, 53
 - hepatitis (AIH), 259, 532, 542
 - thyroiditis, 462
- autoimmunity, 44
- autolysins, 107
- autolysosome, 20
- autonomic nervous system, 188
 - and inflammation, 186
- autophagosome, 20
- autophagy, 132
 - related 16-like 1 gene, 5
 - role of, 5, 20
- Ayurvedic remedies, 697
- azathioprine, 199, 203–5, 238, 255, 287, 317, 360, 385, 423–5, 432
 - and arthritis, 559
 - and CD, 471–7, 680
 - cessation of, 476
 - and colonic disease, 472
 - and conception, 577–8
 - and cutaneous manifestations, 565
 - and hepatotoxicity, 544
 - and IBD, 509
 - medico-legal issues, 708
 - metabolic pathways of, 589
 - and microscopic colitis, 605
 - in pediatric patients, 588–90, 592
 - and postoperative recurrence, 501–3, 505
 - and pregnancy, 574–6
 - and PSC, 539, 541
 - and pyoderma gangrenosum, 565
 - relapse on, 476
 - safety issues, 678, 680–1
 - side effects of, 423, 680
- azithromycin, 622
- B cell activating factor (BAFF), 55–6, 71, 99
- B cells, 31–2, 35–6, 38, 54–5, 65
 - mucosal, 187
 - naive, 98
- Bacillus cereus*, 621
- bacitracin, 623, 632–3
- backwash ileitis *see* ileitis, backwash
- bacteremia, 198, 295, 627
 - portal, 532
- bacteria, 66, 109, 295–6
 - anaerobic, 393
 - and arthritis, 556
 - and carcinogenesis, 509
 - commensal, 93
 - and genetic susceptibility to IBD, 73–5
 - and mucosal immune system, 60–1
 - host response to homeostasis, 92–118
 - infections by, 384
 - interactions with epithelium, 187–8
 - in large intestine, 94
 - luminal, 95, 97
 - lyophilized, 462
 - mechanisms driving IBD, 95–7, 96
 - pathogenic epitopes, 103
 - probiotic, 44, 406
 - reduction in ingestion of, 405–6
 - toxins from, 602
- bacterial flora, 43–4
- bacterial hypothesis, 93
- bacteriophages, 368
- Bacteroides*, 36, 60, 74, 94, 623
 - fragilis*, 94
 - thetaiotaomicron*, 93–4
 - vulgatus*, 93–4, 556
- bacteroides, 279, 623
- Bacteroidetes, 95
- balantidiasis, 653
- Balantidium coli*, 296, 645, 649, 651
- balloon dilation, 257
- balsalazide, 417, 420, 429
 - and CD, 474
 - and hospitalization, 433
 - oral, 430–2
 - and pregnancy, 572
 - toxicity of, 420
 - see also* 5-aminosalicylates
- banana (plantain), 406
- barium enema, 213–15, 235
- barium enteroclysis, 270, 273
- barium sulfate, 269
- barium upper gastrointestinal (UGI) series, 585
- Baron score, 328–9
- basement membranes, composition of, 175
- basiliximab, 132, 376, 426
- basophils, 346
- beclometasone, 338
 - dipropionate, 422
 - rectal, 420
- Behçet's syndrome, 299, 554, 564
- belladonna, 465
- benefits, vs. risks for IBD therapy, 678–92
- benzoate, 405
- Berlin Algorithm Project, 313
- betacellulin, 171
- betamethasone, 216, 420, 422
- bifidobacteria, 279, 393, 406, 623, 636
 - lyophilized, 429, 462
- Bifidobacterium, 60, 74, 93, 95, 395, 463, 699
 - adolescentis*, 623
 - animalis*, 93
 - breve*, 429
 - infantis*, 429
 - lactis*, 398
 - longum*, 429
 - ngulatum*, 623
- bile acids, 537, 605
- bile salts, 602
- bilharzias, 649, 652
- biliary tract, 258–9
 - endoscopy, 259
- bilirubin, 258, 572
- biologic therapy *see* therapy, biologic
- biological agents, and postoperative recurrence, 504
- biological markers (biomarkers)
 - of disease, 6
 - of inflammation, 279–84
- biological pathways, and genetics, 20
- biopsies, 245
 - appearance of UC, 248
 - of the appendix, 249
 - in CD, 248–9
 - appearance of, 249
 - colorectal, 603
 - for dysplasia, 262
 - of gastrointestinal tract, 249–50
 - importance of labeling in, 245
 - indefinite for dysplasia, 523
 - and initial diagnosis of IBD, 246–7
 - misinterpretation of samples, 247
 - of polyps, 247
 - of stomach, 256
 - of terminal ileum, 260
 - of ulcers, 247
- biotherapy, for *C. difficile*, 636
- bismuth, 428
 - carbomer enemas, 463
 - citrate, 428
 - subsalicylate, 428, 602
 - and microscopic colitis, 605
- bisphosphonates, 541
 - and osteoporosis, 671–2
 - and pregnancy, 574
 - therapy with, 594
- bladder, 235, 647
- Blastocystis hominis*, 296
- blastomycosis, South American, 297
- bleeding
 - intractable, 454
 - massive, 482
 - presacral, 446
 - rectal, 648
- blinding (masking), 324
- bloating, 232
- blood flow
 - microvascular, 158, 166–7
 - reduced, 615
 - superior mesenteric arterial (SMA), 267
- blood tests
 - routine, 650–1
 - specific, 651
- bone
 - disease, detection and management, 594
 - fracture risk in IBD, 668–70
 - metabolism and IBD, 665–77
 - resorption, 130
- bone marrow, 34
 - chimeras, 28
 - and IL-1 β , 132
 - suppression, 199
 - transfer model of, 40
 - transplantation, 130
- bone mineral density (BMD), 594, 665–9
- Boswellia*, 697, 699
 - serrata*, 697, 709
 - mode of action, 699
- boswellic acids, 699
- bovine colostrum, 177
 - enemas, 698, 709
 - mode of action, 699
- bowel isolation bag, 447
- Bowman-Birk inhibitor concentrate (BBIC), 697
- Bowman-Birk protein, 429
- breastfeeding, 568, 645
 - and medications, 572–7
- British Society of Gastroenterology, 312, 709–10
- Blue Card scheme, 709

718 Index

- British Society of Rheumatology, 709
 British Thoracic Society, 709
 bromodeoxyuridine, 99
 Brunner glands, 171
 brush border, epithelial, 54
 bubos, inguinal, 662
 Budd–Chiari syndrome, 200, 544
 budesonide, 274, 351, 420, 422, 463, 708
 and CD, 471–2, 474–5
 and colonic disease, 472
 colonic spread of, 417
 enemas, and pouchitis, 462
 and microscopic colitis, 605
 MMX, 472
 and osteoporosis, 670
 in pediatric patients, 588
 and postoperative recurrence, 502
 and pregnancy, 574
 and PSC, 538
 see also corticosteroids
 butyrate, 171, 614
 fecal, 409
- C-reactive protein (CRP), 5, 587, 666
 cachectin, 130
 cachexia, 195–6
 cadherins
 E-cadherin, 178, 513
 N-cadherin, mutants (NCADd), 28–9
 VE-cadherin, 163
Caenorhabditis elegans, 85
 Calcichew D3, 708
 calcineurin inhibitors, 216, 423
 calcitriol, 673
 calcium, 230, 541, 671–3
 deficiency of, 410
 leucovorin, 199
 oxalate, 237, 411
 calprotectin, 267–8
 fecal, 587
Campylobacter, 246, 292, 294–5, 445, 556, 644–5, 648, 652–4
 jejuni, 643–5, 648, 651–2, 655
 Canadian Cancer Society, 687
 Canasa, 417
 cancer
 bowel, family history of, 520
 and clinical supervision, 521
 clinicopathological characteristics in colitis, 520–1
 colitis-associated, 68, 347–8
 colon, 31, 69
 dietary factors and risk of, 403
 molecular associations in, 510
 and PSC, 541
 colorectal (CRC), 216, 287, 508, 649
 causation, 508–10
 dysplasia as precursor to, 509–10
 family history of, 222
 genetic alterations in, 511
 and IBD, 262
 mortality from, 222–3
 and PSC, 222
 risk factors in colitis, 519–20
 in UC, 221–2
 risk factors, 518–19
 and UDCA therapy, 538
 lung, 221
 markers
 of future risk, 514–15
 of progression, 513–14
 rectal, 448
 skin, 681, 683
 small bowel, 482–3
 surveillance
 in IBD, 518–27
 medico-legal issues, 710–11
 see also carcinomas; lymphomas; malignancies
Candida, 297
 albicans, and pouchitis, 462
 candidate-gene approach, 16
 candidiasis, 384, 659, 661, 684
 capillaries, 610–11
 capsaicin, 188
 capsule endoscopy, 5, 271
 carcinogenesis
 of colon, 508–17
 molecular pathways of, 510
 carcinomas, 174
 colonic, 262
 of gall bladder, 537
 hepatocellular, 542
 rectal, 262
 cardiac failure, congestive, 384
 cardiomyopathy, 238
 cardiovascular disease, 205, 221
 care management, 303
 Caremark, 304–5
 carnitine, 19
 β-carotene, 410
 carrageenan, 405
 case reports and series, 333
 case-control studies, 333
 caspase recruitment domain (CARD), 349
 caspase-1, 121, 132, 195
 cataracts, 423
 catecholamines, 700
 cathepsin B proteinase, 646
 CDAI scores, 176–7
 CDP571, 375, 425
 CDP870, 375
 cecitis, spontaneous, 42
 cecum, 37, 41, 233, 247
 removal of, 36
 cefoxitin, 620
 celecoxib, 219
 celiac disease, 53, 87, 100, 183, 203, 256, 462–3, 465, 584
 and microscopic colitis, 602
 Cellcept, 423
 Cellsorba apheresis, 428–9
 cellulitis, 384, 491, 627
 Centers for Disease Control and Prevention (CDC), USA, 637, 683
 central nervous system, and inflammation, 186
 cephalosporins, 433
 and *C. difficile* diarrhea, 622
 certolizumab, 130, 204, 577
 and reactivation of TB, 383
 certolizumab pegol, 373, 374, 385
 and CD, 472, 475, 477–8
 efficacy and safety, 375
 mechanisms of action of, 375
 pharmacokinetics of, 375
 and pregnancy, 577
 safety issues, 678, 681
 CESAME study, 476
 Cesarean sections, 570, 572
 CHARM trial, 374, 475, 478
 cheilitis, 255
 angular, 563
 chemoattractants, 88
 chemokines, 71, 107–8, 133, 143–5, 287, 647
 CC family of, 143–5
 in colitis animal models, 83–4
 CXC family of, 145
 ENA-78, 145
 groups of, 119, 143
 in human IBD, 127–30
 ligands
 CCL2 (MCP-1), 143
 CCL3 (MIP-1), 143–4
 CCL4 (MIP-1), 143–4
 CCL5 (RANTES), 28, 143–4
 CCL19 (ELC), 160
 CCL20 (MIP-3α), 144, 287
 CCL25 (thymus-expressed; TECK), 57, 144–5, 533
 CX3CL1 (fractalkine), 145
 CXCL5 (ENA-78), 145
 CXCL8 (IL-8), 145, 287
 CXCL12 (SDF-1), 145
 MCP-1, 28, 143
 MIP-1α, 143–4
 MIP-1β, 143–4
 MIP-3α, 144
 MIP1a, 28
 in mucosal homeostasis, 119–56
 in murine models of IBD, 122–6
 receptors
 CCR2, 28, 143
 CCR4, 57
 CCR5, 28, 143–4, 532
 CCR6, 56, 144, 287
 CCR9, 57, 144–5, 533
 CXCR2, 145, 287
 CXCR4, 145
 CX3CR1, 145
 SDF-1, 145
 chemoprophylaxis, 521–2
 chemotherapy, 173
 antimicrobial, 653–4, 653–4
 multi-agent, 682
 Child–Pugh model, 535, 540
 Chinese medicine, 695, 709
 modes of action, 698
 chitobioside, 72, 280–1
Chlamydia, 294, 557

 LGV strains of, 293, 295, 662
 chloramphenicol, 622
 chlorhexidine, 637
 chloride secretion, 183–4
 chloroquine, 429

- cholangiocarcinoma, 258–9, 529, 535, 539–42
 cholangiography, 258–9, 530
 cholangitis, 258, 534, 648
 sclerosing, 238, 458, 461, 529
 see also primary sclerosing cholangitis (PSC)
 cholecalciferol, 672
 cholecystitis, 648
 cholecystokinin (CCK), 67, 182
 choledochoscopy, 259
 cholelithiasis, 258
 cholera toxin, 108, 646
 cholestasis, 259, 530, 534, 536–7, 541
 and infliximab, 544
 cholesterol, 543
 cholestyramine, 541, 602, 635
 chondrocytes, 559
 chromoendoscopy, 263, 523
 chromosomal instability (CIN), 510–12
 Churg–Strauss syndrome, 299
 ciclosporine, 700
 Cimzia, 678
 see also certolizumab pegol
 cinnamon, 405
 ciprofloxacin, 393–5, 427–8
 and abscesses, 491
 and CD, 471–2
 and IPS, 465
 in pediatric patients, 588, 590
 and pouchitis, 462–3
 and pregnancy, 573
 see also quinolones
 circumventricular organs, 196
 cirrhosis, 258, 529, 542, 681
 primary biliary (PBC), 534–5, 537, 544
Citrobacter rodentium, 134
 citrovorum factor, 199
 clarithromycin, 622
 and pouchitis, 462
 claudin, 54, 97–8
 Claversal, 417, 502
 clavulanic acid
 and pouchitis, 462
 and pregnancy, 573
 Cleveland Global Quality of Life Scale, 457
 clindamycin, and *C. difficile* diarrhea, 622, 625
 clinical activity index, 328
 see also Crohn’s disease activity index (CDAI);
 perianal disease activity index (PDAI);
 pouchitis disease activity index (PDAI);
 ulcerative colitis activity indices
 clinical care, requirements of, 2
 clinical decision support systems (CDSS), 303,
 315–16
 clinical guidelines, 707
 clinical history, 650
 clinical phenotypes, 2
 clinical practice, and genetics, 21
 clinical presentations, in pediatric IBD, 584–5
 clinical trials, 323–36
 allocation distributions, 331
 of antibiotic therapy
 in CD, 394
 in pouchitis, 396
 in UC, 395
 balancing efficacy and safety in, 334
 design, execution and interpretation in CAM,
 694–5
 in IBD, 696–7
 design of, 714
 endpoints in, 501
 four phases of, 323
 IBD outcome measures, 325–30
 induction of, 325
 limitations of, 332
 maintenance of, 325
 measuring safety in, 332–4
 optimizing efficiency of, 330–1
 placebo vs. active comparator in, 324
 of probiotics
 in CD, 397
 in pouchitis, 398
 in UC, 397
 samples sizes in, 324–5
 superiority vs. equivalence in, 325
 clonidine, 188
 clostridia, 623, 631, 645
Clostridium, 72
 difficile, 95, 247, 292, 294–5, 392, 429, 445, 587,
 620, 645
 antibiotic resistance of, 393
 associated diarrhea, 619–42
 clinical features of, 626–9
 and colonization resistance, 623–
 diagnosis of, 629–32, 630
 epidemiology of, 624–6, 643
 host defense to, 623–4
 pathogenesis of, 620–1, 622
 pathology of, 626
 prevention of, 636–7, 637
 relapse in, 634
 risk factors for, 621–3
 treatment of, 632–6
 without pseudomembrane formation,
 627
 associated disease (CDAD), 619–42
 asymptomatic carrier state, 627, 643
 BI/Nap1/027 strain, 295, 619–20, 624–34
 colitis, 456, 458, 654–5
 culture of, 631
 endoscopic diagnosis of, 631–2, 652
 laboratory tests for, 630–1
 and pouchitis, 462–3
 and SCAD, 615
 stool tests for, 630
 toxins (CDT A & B), 586, 619–21, 622, 624,
 629, 631, 645–7, 651
 vaccines for, 634
 novyi, 621
 paraperfringens, 299
 perfringens, 299, 627
 septicum, 299
 sordellii, 621
 clotting factors, 164
 coagulation, 158
 cascade, 157
 disorders of, 200–2
 coagulation–anticoagulation pathways, 165
 cobalamin, 202
 cobblestoning *see* Crohn’s disease, oral
 (cobblestoning)
- cocciidiomycosis, 684
 codeine, 411, 433
 cohort studies, 333
 colchicine, 205
 and PSC, 539
 colectomy, 184, 200, 212–15, 217, 219–20, 434, 634
 after surveillance colonoscopy, 263
 in ASUC, 216
 cumulative rates of, 220
 and dysplasia, 263
 short-term rate of, 216
 subtotal (STC), 444, 455
 in UC, 252
 colitides, 5
 of infectious origins, 643–57
 colitis, 3
 acupuncture in, 698
 acute, medico-legal issues, 709–10
 amebic, 246, 586, 647, 649, 651
 angiogenic mediators in, 162–3
 animal models of, 164
 anti-angiogenic gene expression in, 163–4
 anti-CD40 agonist-induced, 31
 antibiotic-associated, 586
 bacterial, 292, 648–9
 causes of, 5
 clinical evidence of, 34
 clinicopathological characteristics of CRC in,
 520–1
 collagenous, 298, 601–8
 histopathology of, 604
 see also colitis, microscopic
 and colon carcinogenesis, 508–17
 colonoscopic finding of, 248
 cytotoxin-induced, 646–7
 differential diagnosis of, 292–302, 293
 distal, 32–3, 213–4
 diversion, 297–8, 609–10, 613–14, 626
 clinical features of, 614
 treatment of, 614
 diverticular (SCAD), 297, 610, 614–15
 clinical features of, 614–15
 treatment of, 615
 DSS-induced, 29–31, 44, 68, 121
 eosinophilic, 299
 extensive, 213, 215
 extent and risk of CRC, 519
 forms mimicking IBD, 613–16
 frequency of complications in, 214
 fulminant, 433, 455, 629, 649
 haptten-induced, 184
 helminthic, 649
 hemorrhagic, 645
 and IL-18, 126
 idiopathic, 69
 IL-10 pathway to, 39
 indeterminate, 4, 250, 281–2, 457, 586
 symptoms of, 4
 infantile, 409
 infectious, 139, 246, 292–5, 643–57
 antimicrobial chemotherapy in, 653–4, 653–4
 clinical features of, 647–9
 diagnosis of, 649–52
 endoscopic appearances, 651
 endoscopy in, 294

720 Index

- colitis (*Cont.*)
- enteropathogens responsible for, **645**
 - epidemiology of, 644–5
 - etiology of, 645
 - histology in, 294–5, **294**
 - history of, 292–3
 - in immunocompetent individuals, **293**
 - investigation of, 650
 - laboratory evaluation of, 293–4
 - pathogenesis of, 645–7
 - pathogenetic processes in, 646–7
 - physical examination for, 292–3
 - presenting symptoms of, 292
 - risk factors for, **644**
 - treatment of, 652–4
 - infectious agents in, 295–7
 - and intestinal infection, 654–5
 - ischemic, 295, 297, 610, 615–16
 - clinical features of, 615–16
 - treatment of, 616
 - left-sided, 213, 215, 220–1, **417**
 - lymphocytic, 298, 601–8
 - histopathology of, 603–4
 - see also* colitis, microscopic
 - medication-associated, 298–9
 - microscopic, 298, 601–8
 - clinical presentation of, 603
 - differential diagnosis of, 603, **603**
 - etiology of, 601–2
 - immune mechanisms in, 605
 - incidence of, 601
 - pathogenesis of, 604–5
 - pathology of, 603
 - pathophysiology of, 605
 - treatment of, 605–6
 - minimal change, 247
 - moxibustion in, 698
 - murine, 70
 - neutropenic, 299
 - non-specific, and intestinal infection, 654–5
 - oxazolone-ethanol-induced, 32–3
 - oxazolone-mediated, 87, 105, 137, 139
 - perpetuation of, 40
 - protozoal, 649
 - pseudomembranous (PMC), 249, 586, 619, 622, 626, 626, 627–9, 627
 - and radiation, 299
 - risk factors for CRC in, 519–20
 - severe, 455–6
 - sexually transmitted, **295**
 - spontaneous, 36–7, 82
 - substantial, 213
 - with systemic disease, 299
 - TNBS-ethanol enema-induced, 31–2, 87, 133
 - Total, 213–15, 220–1
 - toxic, 433
 - treatment options for CRC in, 521–5
 - treatment with PPAR γ agonists, 346–7
 - triggering of, 34
 - ulcerative, 3–4, 6, 64, 231, 626
 - acute severe (ASUC), 216–17
 - age effect in, 215
 - and amyloidosis, 204–5
 - antibiotics in, 393–4
 - clinical trials, **395**
 - antimicrobial responses, 72
 - association with PSC, 535–6
 - backwash ileitis in, 250
 - Baron score, 328–9
 - biliary and colorectal cancer in, 536–7
 - C. difficile* infection in, 629
 - and CD4 accumulation, 84
 - and Chinese medicine, 695
 - cholangiogram of, 530
 - clinical activity indices, 328–30, **329**
 - clinical score, 328
 - and colectomy *see* colectomy
 - course of disease, 217
 - and CRC, 221–2, 508
 - CRP responses, 5
 - demographics of, 13–14
 - diagnostic criteria for, 213
 - and diet, 409
 - differentiation from CD, 281–2, **298**
 - disease behavior in, 4
 - disease extent in, 213
 - dynamics of, 214–15
 - distal, 429–32
 - distinguishing states of, **417**
 - and dysplasia, 458–9
 - elective procedures for, 445–57
 - endoscopic differentiation of, 259
 - endoscopic indices for, 329
 - etiology of, 37
 - extensive, 432
 - extent at diagnosis and follow-up, 213–14, **214**
 - and Geboes index, 330
 - genetic advances in, 20–1
 - global scales for, 328
 - and health education, 223
 - herbal remedies in, 695–8
 - histological indices for, 329–30
 - histopathology of, 260, **260**
 - and HIV/AIDS, 661, **661**
 - incidence of, 10–12
 - indications for treatment, **430**
 - influences on natural history, 218–20
 - and inhibitory nerves, 185
 - Lichtiger index of, 328
 - macroscopic findings in, **261**
 - Mayo score for, 329, **418**
 - mimicry of CD by, 249
 - mortality in, 220–1
 - and motility, 184
 - mucosal (MUC), 444
 - and NFKB1 polymorphism, 74
 - nutritional therapy for, 593
 - outcomes, 217
 - measures for, 328–30
 - patient-defined remission in, 328–9
 - pediatric and adolescent, 218, 328–9
 - activity index, 328
 - potential confounders in natural history studies, 212–13, **213**
 - Powell-Tuck index for, 328
 - and pregnancy, 219, 458, 570–1
 - probiotics in, 396–7
 - clinical trials of, **397**
 - and PSC, 222, **529**
 - Rachmilewitz index for, 328
 - rates of surgery in, **220**
 - refractory, 432–3
 - Riley index for, 330
 - risks
 - associated with, 679
 - of CRC in, 518–19
 - St Mark's index for, 328
 - Seo index for, 328
 - as separate entity from UP, 217–18
 - severe, 433–4
 - severity of attacks, -215–16, **215**
 - simple clinical colitis activity index for, 328
 - and smoking, 219
 - and stress, 189
 - surgical considerations for, 444–5
 - institute results on, 457–8
 - Sutherland index for, 329
 - symptoms of, 4, 259–60
 - treatment of
 - goals for, 417–29
 - guidelines algorithm, 431
 - indications and approaches, 429–34
 - therapeutic, 415–43
 - Truelove and Witts severity index, 328, **418**
 - modified, 328
 - typical pattern of, 455
 - and ulcerative proctitis (UP), 212–27
 - variation in microscopic appearances in, 248
 - unclassified, 250
 - viral, 649

colitis-associated colon carcinogenesis (CAC), 508–17

 - causation (genes vs. environment), 508–10
 - genetic alterations in, **511**
 - molecular associations in, 510

colitogenic (Th1) effector cells, 160

collagen, 175, 178, 604–5

collagenase (MMP-1), 175

colon, 33–4, 37, 41, 140, 172, 347

colitis-associated carcinogenesis of, 508–17

 - microbiota of, 94–5
 - right, 230

colonic disease, 231

 - active, 472

colonic epithelial lymphocytosis, 604

colonization resistance, and CDAD, 623, 635–6

colonocytes, 172, 603–4, 646

colonoscopy, 213–14, 257, 281

 - and cancer surveillance, 262–3
 - cost-effectiveness of, 317
 - counseling for, 711
 - disease activity monitoring, 261–2
 - hindgut, 261
 - leading to colectomy, **263**
 - pediatric, 585
 - and SCAD, 614–15
 - surveillance, 222
 - see also* ileocolonoscopy

colostomy, blow-hole, 444, 456–7, 457

comb sign, 269, 270, 272, 273, 613

COMMIT trial, 477

Community Interventions and Epidemiological Technologies (CIET) cycles, 307

complement system, 197

- complement-dependent cytotoxicity (CDC), 366
 complementarity-determining regions (CDRs), 363, 366
 region 3 (CDR3), 99
 complementary and alternative medicine (CAM), 693–704
 and legal pitfalls, 708–9
 modes of action of, 698–700
 other modalities in, 698
 regulation of, 700–1
 side effects of, 700
 use of, 693–4
 in IBD, 694–5, **694**
 compliance, 476
 in pediatric patients, 595
 complications
 in CD, 234–6
 neurologic, 238
 psychiatric, 238
 renal and urologic, 237
 vascular, 237–8
 computed tomography (CT), 254, 266–78, 554, 586, 613, 616, 626
 in *C. difficile* colitis, 628
 enterocolitis, 266, 268–71
 enterography (CTE), 266, 268–71
 diagnostic accuracy of, 271
 conception, 571
 male medications during, 577–8
 confocal laser endomicroscopy, 263
 congenital abnormalities, 570
 congestive heart failure (CHF), 684
 conjunctivitis, 648
 constipation, 296, 558
 idiopathic, 604
 contraceptives, oral, 297, 564
 control groups, 324
 Coombs' test, 200
 Copenhagen study, 212, 217, 239, 470
 copper, deficiency of, 198
 corticosteroids, 203, 230, 233, 236, 239, 270, 284, 338, 360, 420–3
 and bone fractures, 668–9, **670**
 and CD, 471
 and conception, 577
 dependence on, 327
 in the elderly, 234
 in herbal remedies, 700, 709
 intravenous, 421–2, 432
 and legal pitfalls, 707–8
 and microscopic colitis, 605
 oral, 421–2
 and osteoporosis, 665–6, 670
 in pediatric patients, 588, 592
 and pouchitis, 463
 and pregnancy, 573–4
 and PSC, 538
 and pyoderma gangrenosum, 565
 and pyostomatitis vegetans, 563
 rectal, **421**, 422, 431
 and remission, 431
 toxicity of, 422–3, 432
 see also budesonide; prednisolone; steroids
 corticotropin, 420–2
 intramuscular, 422
 cortisol, 338–9, 588, 700
 cortisone, 420–2
 cost-benefit analysis, 310
 cost-effectiveness analysis, 309–10
 CpG island methylator phenotype (CIMP), 513
 cramping, 233, 603, 647
 Crohn's and Colitis Foundation of America, 710
 Crohn's disease, 3–4, 67
 abscesses in, 236
 activity index (CDAI), 261, 267, 272, 325–7, **326**, 330, 471, 670, 695
 pediatric, **326**
 and amyloidosis, 204–5
 antibiotics in, 393
 clinical trials of, **394**
 antimicrobial responses in, 72
 and anxiety, 238
 appendiceal, 233
 C. difficile infection in, 629
 CD4 accumulation in, 84
 classic features of, 248
 classification of, 4, **236**
 clinical course of, 238–9
 clinical features of, 229
 clinical presentations in, 228–34
 common presentations, 230–1
 less common presentations, 231–3
 oral manifestations, 233
 presenting complaints, 228–30
 clinical trial outcome measures, 325–8
 and colonic disease, 231
 complications of, 234–6
 cardiac and pulmonary, 238
 renal and urologic, 237
 vascular, 237–8
 costs of, 679
 and CRC, 5, 508, 525
 cutaneous, 565
 delayed diagnosis of, 710
 demographics of
 and depression, 189, 238
 dietary intervention studies, 403–6
 differentiation from UC, 281–2, **298**
 disease behavior in, 4
 disease location in, **230**
 duodenal, 232
 in elderly patients, 233–4
 endoscopic differentiation of, 259
 endoscopic index of severity (CDEIS), 261, 272, 327–8, **499**
 enteral feeding in, 406, **407–8**
 esophageal, 232
 fistulas in, 235–6
 and flagellins, 42, 69
 and fractalkine, 145
 gastric, 232
 and gene polymorphism, 74
 herbal remedies for, 697–8
 histopathology of, 260, **260**
 and HIV/AIDS, 661, **661**
 and ileal disease, 230–1, 233
 and ileal pouch formation, 446
 ileocecal, 471–2
 preventing relapse of, 474–5
 and ileocolonic disease, 230, 233
 incidence of, 10–12
 and innate immunity, 64–5
 defective, 73
 and IPAA, 490–1
 in Japan, 402
 jejunal, 232–3
 macroscopic findings in, **261**
 metastatic, 565
 mimicked by UC, 249
 and mortality, 221, 240–1, 240
 motility changes in, 184
 mucosal biopsies in, 248–9, 249
 natural history of, 238–41
 neurologic manifestations in, 238
 nutritional therapy in pediatric patients, 591–3
 oral (cobblestoning), 233, 237, 255, 260, 563
 and pancreatic disease, 238
 pattern prediction at diagnosis, 470
 perforating, 500
 perianal, 481–97
 and perianal disease, 230–1
 postoperative recurrence of, 406, 498–507
 assessment of, 499
 risk stratification in, 498–500
 of the pouch, 461, 464–5
 and pregnancy, 219, 570–1
 probiotics in, 396
 clinical trials of, **397**
 prognosis of, 238–41
 and PSC, 529
 psychiatric manifestations in, 238
 and quality of life, 240
 relapse in, 239
 epidemiology of, 470–1
 prevention of, 473–5
 and treatment dilemmas, 475
 remission management in, 473–8
 risks associated with, 679, **679**
 role of IL-21 in Th1 cell responses
 Rutgeerts endoscopic grading scale for, 261–2, **262**, 328
 serologic profiles of, 236–7
 serological markers for, 6
 simplified endoscopic activity score (SES-CD), for, 261, 327–8
 small bowel, 257
 surgery for, 485–9
 steroid-dependent, 475–6
 steroid-refractory, 476
 strictures in, 235
 surgery in, 239, 481–97
 gastroduodenal, 489–90
 general considerations for, 483–5
 impact of therapy on, 485
 indications and timing of, 481–3
 laparoscopic, 484–5
 large bowel, 490–1
 preoperative evaluation and management, 483–4
 small bowel, 485–9
 susceptibility to, 39
 symptoms of, 4, 228–30, 260
 therapeutic approaches to treatment in, 469–70
 treatment of, 471–2
 algorithm for, 504

722 Index

- complications of (*Cont.*)
 - tumor sites in, 525
 - upper gastrointestinal involvement in, 231–3
 - utility score for, 679
- crypt cells
 - distortion of, 294
 - intestinal, 71
 - proliferation of, 183
- cryptidins, 17, 31, 71, 106–7
- cryptitis, 294, **604**
- cryptococcosis, 384, 684
- cryptopatches, 99
- cryptosporidiosis, 659
- Cryptosporidium*, 586
- crypts of Lieberkuhn, 54
- cuffitis, 461, 463–4
- culture, stool, 651
- Curcuma longa*, 351, 697
- curcumin, 87, 351, 405, 613, 697
 - mode of action, 699
- Cyanobacteria, 95
- cyanocobalamin, 198
- cyclooxygenase inhibitors
 - COX-1, 171
 - COX-2, 56, 171, 509, 558
 - inducible, 184
 - and UC, 219–20
- cycloserine, 620
- cyclosporin, 216, 252, 255, 298, 360, 423–4
 - A (CsA), 589–90
 - in acute colitis, 709–10
 - oral, 434
 - and pregnancy, 575
 - and PSC, 538, 541
 - and pyoderma gangrenosum, 565
 - rescue therapy with, 434
 - side effects of, 424, 590
 - cystoscopy, 235
 - cystourethrogram, 235
 - cytokines, 29, 40–1, 71, 97, 108–9
 - in animal models
 - for colitis, **83–4**
 - for murine IBD, **122–6**
 - anti-inflammatory, 138–41, 377–8
 - and barrier function, 106, 183
 - and epithelial cells, 184
 - and food intake, 196
 - in human IBD, **127–30**
 - inhibition of pro-inflammatory signaling by, 369–82
 - in mucosal homeostasis, 119–56, 120
 - pathways in gut inflammation
 - pro-inflammatory, 120–38, 188, **197**
 - production in epithelium, 187
 - receptors, 109
 - in remission and relapse, 174–5
 - and T cell classification, 26–27
 - types of, 119
 - Th1, 121–34, 174
 - Th2, 136–8, 174
 - Th17, 134–6, 174
 - unclassified, 141–3
 - cytolysis, contact-dependent, 646
 - cytomegalovirus (CMV), 107, 247, 249, 251, 294–5, 384, 445, 586–7, 645, 649, 652, 680
 - and HIV/AIDS, 659
 - and pouchitis, 462–3
 - retinitis, 369
 - cytotoxic T lymphocyte antigen-4 (CTLA-4), 60
 - cytotoxicity assay, 630–1
 - cytotoxins, 646
 - D2E7, 425
 - daclizumab, 132, 376, 426
 - dapsone, and pyoderma gangrenosum, 565
 - data, framing of, 687
 - DEC-205, 102
 - decision aids, 687
 - decision analysis, 334
 - decision support (shared decision making), 686–8
 - computerized systems for, **315–16**
 - defensins, 31, 54, 71, 97, 106–7, 188
 - α-defensins, 17, 54, 71, 106
 - β-defensins, 54, 71, 107
 - defensive medicine, 705
 - dehydroepiandrosterone sulfate (DHEAS), 667
 - dehydroepiandrosterone (DHEA), 429
 - delivery, vaginal, 572
 - dementia, 314
 - demographics, of IBD, 13–14
 - demyelinating disease, 238, 385
 - dendritic cells (DCs), 35, 54, 65, 72, 98, 102, 121, 361, 376
 - mucosal, 56
 - Denoviller's fascia, 447
 - deoxycholic acid (DCA), 538
 - deoxyribonucleic acid (DNA)
 - aneuploidy, 509, 511
 - complementary (cDNA), 368
 - arrays, 285–6
 - tests, 651
 - and TLR9, 70
 - depression, 238, 314
 - in IBD, 189
 - in pediatric patients, 594–5
 - dermatitis, atopic, 137
 - dexamethasone, 338, 341, 344
 - dextran sulfate sodium (DSS), 20, 29–31, 68, 105
 - diabetes, 471
 - mellitus, 105, 423
 - types 1 & 2, 205
 - diacyl lipopeptides, 66
 - diagnosis
 - age at, 520
 - of IBD in HIV patients, 661, **662**
 - of microscopic colitis, **603–4**
 - new approaches to, 279–91
 - of pediatric IBD, **585–6**
 - and postoperative recurrence in CD, 498–507
 - UC extent at, 213–14, **214**
 - diarrhea, 31, 33, 38, 95, 182–3, 196, 215
 - antibiotic-associated, 627
 - bloody, 643, 648, 661
 - Brainerd, 604
 - C. difficile*-associated, 619–42, 653
 - in CD, 229
 - chronic, 35
 - watery, 601
 - epidemic, 604
 - and IL-18, 126
 - and ileal disease, 230
 - in infants, 572
 - infective, 649
 - mechanism of, 605
 - normal colonoscopic findings in, 247
 - paradoxical worsening of, 419
 - in pediatric patients, 591
 - traveler's, 625, 645
 - watery, 645, 648, 653
- didronel, 541
- Dientamoeba fragilis*, 586
- diet
 - avoidance of harmful components, 403–5
 - beneficial nutritional components of, 405
 - and CAC, 509
 - elemental and semi-elemental, 592
 - in IBD, 402–3
 - intervention studies, 403–6
- diferuloylmethane, 87
- diffuse jejunoileitis, 233
- digoxin, 297
- dihydrofolate reductase, 199
- dilation, 259
 - defective, 167
- diltiazem, 491
- dimethyl sulfoxide, 205
- dinitrochlorobenzene, 166
- dinitrophenylated keyhole limpet hemocyanin (DNP-KLH), 33–4
- diphenoxylate, 433, 632
- disease
 - activity
 - indices of, 323–6
 - see also* Crohn's disease activity index (CDAI); perianal disease activity; index (PDAI); pouchitis disease; activity index (PDAI); ulcerative colitis activity indices
 - in pregnancy, 570–1, 571
 - biomarkers of, 6, 587
 - classification of, 236
 - pathogenesis of, 3
 - perianal, 572
 - predictor of susceptibility to, 284
 - risks of, 679–80
- disease management (DM), 303–22
 - decision-making in, 311–12
 - economic factors in, 307–310
 - general components of, **306**
 - guidelines for, 311–14
 - and healthcare costs, 308–9
 - in IBD, 317
 - implementation of, 314–17
 - importance of, 311
 - Purchasing Consortium and Advisory Council, 305
- disodium cromoglycate, 428
- dissection, perineal, 454
- divalent metal transporter 1 (DMT1), 198
- diversion colitis *see* colitis, diversion
- diverticular colitis *see* colitis, diverticular
- diverticular disease, 5, 248

- diverticulitis, 614
 acute, 139, 614
 diverticulosis, 614
 docosahexenoic acid, 427
 Doppler blood flow, 267
 Doppler sonography, 587
 doxycycline, 632, 662
 and pouchitis, 462
 drains, 492
Drosophila, 85, 109
melanogaster, 109
 drugs
 acid inhibitory, 645
 anti-angiogenic, 163–4
 anti-inflammatory, in IBD, 346–7
 anti-TNF, 681
 and disease management, 304
 factors influencing use and cost, 310–11
 for HIV/AIDS, 659
 immunosuppressant, 360, 589–90
 interactions with herbal remedies, 700
 and malpractice claims, 707–9
 toxicity of, 714
 UDCA, 258, 520, 533, 536–9
 dual-energy X-ray absorptiometry (DEXA), 594, 667
 duodenal bulb, 231
 duodenal loop, 231
 duodenitis, 256
 duodenum, 87, 171, 231, 256–7
 dysbiosis, 43, 107
 dyschezia, 464
 dysentery, 3, 296, 653
 dyspareunia, 235
 dyspepsia, 232
 dysphagia, 232
 dysplasia, 29, 31, 222, 317, 461, 520–1
 and aneuploidy, 511
 biopsies for, 262
 cervical, 569, 680
 classification of, 522–3
 and severity, 521
 and colectomy, 263
 colorectal, 258
 diagnosis of, 251–2, 522–3
 flat, 509
 in mucosa, 523–4
 high-grade (HGD), 445, 509–14, 523
 hypohidrotic ectodermal and immunodeficiency (HED-ID), 349
 low-grade (LGD), 222, 509–14, 523
 mimicking, 252
 polypoid, 515
 as precursor to CRC, 509–10
 in raised lesions, 524
 and UC, 458–9
 dysplasia-associated lesions or masses (DALMS), 247, 252, 263, 445, 515, 520, 523, 711
 dysuria, 235
 edema, 177, 232, 296, 626
 efavirenz, 659
 effector cells, 45
 efferent nerves, and inflammation, 185
 eicosanoids, 347, 592
 eicosapentanoic acids, 108–9, 427, 593
 eicosapentanooids, 405
 ejaculation, retrograde, 569
 elderly, CD presentation in, 233–4
 embolism, pulmonary, 200
 empyema, 627
 entricitabine, 659
 emulsifiers, in diet, 404–5
 ENACT trials 1 & 2, 380, 384
 encephalomyelitis, autoimmune, 139
 ENCORE trial, 380
 endocarditis, 238
 endocytosis, 367
 endomicroscopy, 523
 confocal laser, 263
 endopeptidases, 88
 endoplasmic reticulum, 30
 endorphins, 186
 endoscopic balloon dilation, 255–6
 endoscopic retrograde cholangiopancreatography (ERCP), 259, 534, 539–40
 endoscopic ultrasound, 259
 endoscopy, 279–91
 for *C. difficile*, 631–2
 and cancer surveillance, 262–3, 522–5
 capsule, 257–8, 499, 587
 wireless, 232–3, 237
 and CD, 237
 in diagnosis and treatment of IBD, 254–65
 in disease activity monitoring, 261–2
 of foregut, 256–7
 indices for UC, 329
 in infectious colitis, 294
 of midgut, 257–8
 protocol for, 522–3
 for PSC, 539
 rectal, 651
 endothelial cells, 134, 142
 human intestinal microvascular (HIMECs), 612
 endothelial derived relaxing factor (EDRF), 611
 endothelins, 157, 611, 613
 endothelin-1 in inflammation, 166–7
 endothelium, microvascular of, 609
 enemas, 177, 422, 428–9
 anesthetic, 428
 barium, 213–14, 433
 bismuth, 463
 bovine colostrum, 698
 budesonide, 462
 Chinese medicine, 695
 corticosteroid, 587
 epidermal growth factor, 426
 fecal, 636
 fiber, 614
 gastrograffin, 446
 glutamine, 463
 mesalamine, 429–31, 463
 prednisolone, 588
 SCFA, 463
 small bowel, 483
 steroid, 615
 suspension, 419
 enoxaparin, 427
 entactin, 175
Entamoeba
dispar, 645
histolytica, 292, 294, 296, 645–6, 649, 651–2
 enteral feeding, 403
 in CD, 407–8
 enteric flora, 43
 enteritis, 30
 diffuse, 36
 regional, 3
 spontaneous, 42
 ulcerative, 3
Yersinia, 653
 entero-endocrine cells (EECs), and inflammation, 186
 enterobacteria, 279, 556
 Enterobacteriaceae, 94
 enterochromaffin cells, 186
Enterococcus, 94–5
faecalis, 93
 enterocolitis, 30, 39
 infectious, 586
 enterocytes, 27, 54, 140, 172
 enteroglia cells, 188
 and inflammation, 185
 enterography
 CT, 257
 utilization of, 274
 enteropathogens, 644
 and infectious colitis, 645
 inflammatory responses to, 647
 enteropathy
 autoimmune, 587
 gluten-sensitive, 52
 enteroscopy, 232, 266–78
 push, 257–8
 single and double balloon, 257–8
 sonde, 257
 enterotoxin, 646
 environment
 and carcinogenesis, 508–10
 germ-free (GF), 93
 specific pathogen-free (SPF), 93
 environmental factors
 and arthritis, 555–7
 and IBD, 43–4
 enzyme-linked immunosorbent assay (ELISA), 296, 629, 631, 651, 666
 enzymes
 deubiquinylation (A20), 30
 proteolytic, 646
 eosinophilia, 138, 299, 649
 eosinophils, 137, 346, 604
 epidemiology
 of IBD, 9–15
 diet in, 402–3
 pediatric, 584
 epidermal growth factor (EGF), 171–2
 enemas, 426
 heparin-binding, 171
 receptor (c-erb1), 171
 episcleritis, 559
 episiotomy, 572
 epithelial barrier, 82, 106
 dysregulation of, 97
 intestinal, 97–8

724 Index

- epithelial cells
 - biliary (BECs), 533
 - cross-talk with immune cells, 107–10
 - and cytokine production, 187
 - and cytokines, 184
 - effect of inflammation on, 183–4
 - fluid and ion transport in, 183–4
 - growth, differentiation and apoptosis of, 183
 - in the immune response, 186–8
 - intestinal (IECs), 25–7, 92, 96, 98, 121
 - as APCs, 101–4
 - general features of, 102
 - CD1d ligand on, 104–5
 - and glucocorticoids, 346
 - influence of polarity on antigen presentation, 103
 - interaction with T cells
 - CD4, 102–3
 - CD8, 104
 - MHC class II processing by, 102–4
 - and lymphocytes, 187
 - see also* epithelium
 - epithelial–mesenchymal cross-talk, 173
 - epithelium
 - as defense layer, 53–5
 - follicle associated (FAE), 55, 97
 - interactions with bacteria, 187–8
 - intestinal healing regulation, 178
 - invasion of, 647
 - permeability changes in, 183
 - re-establishing continuity of, 170
 - see also* epithelial cells
 - epitopes, 367
 - pathogenic, 103
 - Epstein–Barr virus (EBV), 141, 160, 204, 680
 - equivalence trials, 325
 - erectile dysfunction, 447, 569
 - ergocalciferol, 672
 - erythema multiforme, 648
 - erythema nodosum, 553–4, 563–4, 648
 - erythrocyte sedimentation rate, 587
 - erythromycin, 622, 653
 - erythrophagocytosis, 198
 - erythropoietin, 198–9
 - Escherichia*
 - coli*, 5–6, 93, 95, 106–7, 136, 187, 280, 393, 556, 651
 - 0157:H7 strain, 294–5
 - adherent-invasive (AIEC), 393, 405
 - enterohemorrhagic (EHEC), 292, 295, 643–4, 646, 648, 651, 653
 - enteroinvasive (EIEC), 295, 647–8, 653
 - enteropathogenic, 63
 - enterotoxigenic, 645
 - hemolytic strains, 395
 - Nissle 1917 strain, 396, 429
 - outer membrane porin C (OmpC), 462
 - toxin, 621
 - esophageal disease, 473
 - esophagitis, 255, 671
 - esophagogastroduodenoscopy (EGD), 254–6, 281
 - of foregut, 256–7
 - esophagus, 231, 255–6
 - EspA, 646
 - EspB, 646
 - EspD, 646
 - estrogen receptor, 513
 - etanercept, 310–11, 373, 373, 374–5
 - and arthritis, 558
 - and heart failure, 384
 - and neurologic events, 385
 - and PSC, 539
 - and reactivation of TB, 383
 - ethambutol, 653
 - ethanol, and mucosal penetration, 31–2
 - ethylcellulose, 419
 - ethylene oxide, 637
 - etidronate, 671
 - Eubacteria, 97
 - Eubacterium*, 60, 699
 - Eudragit
 - coated, 502
 - L, 419
 - S, 419–20
 - European Agency for the Evaluation of Medical Products (EMA), 327
 - European Collaborative Study on IBD (EC-IBD), 213
 - European Crohn's and Colitis Organization (ECCO), 312
 - European Society for Pediatric Gastroenterology, Hepatology and Nutrition, 586
 - European Union Traditional Use Directive, 700
 - evidence-based care, 303
 - exocytosis, 368
 - expressed sequence tags (ESTs), 285
 - extracellular matrix (ECM), 162
 - molecules, 175
 - eyes, conditions associated with IBD, 553–61
 - ezrin, 646
 - factor V, 201
 - Leiden, 201
 - factor VIII, 201
 - Faecalibacterium prausnitzii*, 393
 - familial adenomatous polyposis (FAP), 461, 509
 - Fas/FasL pathway, 58
 - fast food, 403
 - fat, 403–4
 - creeping, 237
 - halo sign, 248
 - peri-enteric stranding, 269
 - wrapping, 446
 - fatigue, 195
 - and PSC, 258, 541
 - fatty acids, anti-inflammatory, 405
 - fatty liver *see* liver, fatty
 - FcRn, 102
 - fecaluria, 235
 - feces, testing of, 651
 - fecundability ratio (FR), 569
 - feeding
 - enteral in CD, 406
 - intravenous, 403
 - fenfluramine, in herbal remedies, 700, 709
 - Fenton's reaction, 198
 - ferritin, 198, 409
 - ferroportin, 198
 - fertility
 - female, 568–9
 - in IBD, 568–83
 - male, 569–70
 - and sexual function, 568–70
 - and surgery, 569
 - fetal aminopterin–methotrexate syndrome, 574
 - fever, 195–6, 198, 647
 - in CD, 230
 - fiber, 403–4
 - oral, 615
 - soluble plant, 406
 - fibrin, 163–4, 256
 - glue, 492
 - plugs, 492
 - fibrinogen, 164, 201
 - fibroblast growth factor (FGF)
 - 7 (FGF-7), 172, 426
 - 10 (FGF-10), 426
 - basic (bFGF), 173
 - family, 172–3
 - fibroblasts, 141–2, 170
 - stromal, 176
 - synovial, 205
 - fibronectin, 175, 178
 - FibroScan, 529
 - fibrosis, 40, 137, 140, 171, 178–9, 589, 681
 - inflammation-driven, 89
 - periductular, 529
 - fibrostenosis (FS), 269, 282–3, 498
 - FibroTest, 529
 - filgrastim, 142
 - filopodia, 170
 - finger clubbing, 649
 - Firmicutes, 69, 95
 - fish oils, 409, 427, 592–3
 - and pregnancy, 577
 - fissures, 491
 - fistulas, 182, 229–30, 482, 491–4, 590
 - after appendectomy, 233
 - in CD, 235–6
 - colocutaneous, 235
 - cologastric, 235
 - colonic, 232
 - colovesicular, 235
 - complex, 492–3
 - internal, 272
 - diagnostic tests for, 235
 - duodenal, 489–90
 - enterocolonic, 235
 - enterocutaneous, 235–6, 270
 - enteroenteric, 235
 - enterovesicular, 235
 - esophageal, 256
 - esophagobronchial, 232, 235
 - external, 235
 - gastrosplenic, 235
 - and infliximab, 492
 - internal, 234–5, 272
 - intractable, 3
 - low rectal, 494
 - perianal, 231, 234–6
 - rectovaginal, 235, 493–4, 493
 - simple, 491–2
 - splenic, 232
 - transphincteric, 492
 - US tracking of, 268

- fistulization, 260
 fistulizing disease, 234
 assessment of, 327
 fistulotomy, 492
 FK506, 423
 in pediatric patients, 590
 flagellins, 19
 CBir1, 6, 19, 280
 molecular model of, 42
 and role of TLR5, 69
 flap advancement, 493, 494
 flatus, per vagina, 235
 flora
 bacterial, 43–4
 colonic, 94
 oral, 94
Flos sophorae, 695
 fluid transport, in epithelial cells, 183–4
 fluorodeoxyglucose (FDG), 273–4
 fluoroquinolones, 619
 and *C. difficile* diarrhea, 622
 5-fluorouracil, 298, 428
 and *C. difficile* diarrhea, 623
 fluticasone, 420, 422
 fluvoxamine, and PSC, 541
 foam, rectal, 419
 folate, 199, 202, 403
 deficiency of, 410, 509, 536
 folic acid, 199, 237, 563, 574, 589, 681, 708
 folinic acid, 199
 follicle-associated epithelium (FAE), 55, 97
 follow-up, UC extent at, 213–14
 fontolizumab, 377
 food
 anti-inflammatory components, 405
 antigens, 183
 Food and Drug Administration (FDA), USA, 589
 drug categories in pregnancy, 572
 safety surveillance by, 678
 foregut, 254–7
 duodenum, 87, 171, 231, 256
 endoscopy of, 256–7
 esophagus, 231, 255–6
 oral cavity, 255
 stomach, 174, 231, 256
 formivirsin, 369
 5-formyl tetrahydrofolate, 199
N-formylmethionylleucylphenylalanine (FMLP), 187
 fornix, 235
 foscarnet, 653
 fosfomycin, 653
 fractalkine, 145
 frankincense, 697
 Freund's adjuvant, 34, 44
 fructooligoaccharides, 409
 fructose intolerance, 465
 fruit, 403
 α -1,2-fucosyltransferase (hFUT1), 37
 fungemia, 636
 fungi, 297
 infections by, 384
 fusidic acid, 632–3
 Fusobacteria, 95
Fusobacterium, 60
 varium, 93
 G proteins, Gi2, 29
 gadolinium, 272–3, 557, 586
 GAIN study, 374, 478
 galactooligosaccharides, 406
 α -galactosylceramide, 104–5, 137
 gallbladder, 184
 gallstones, 184, 543, 543
 ganciclovir, 653
 ganglioside M1 (GM1), 102
 gangrene, 616
 gastric acid, 624, 645
 gastric antrum, 231
 gastrin, amidated, 173
 gastrinomas, 603
 gastritis, *H. pylori*, 86–7
 gastroduodenal disease, 473
 surgery for, 489–90
 gastroenteritis, 295
 gastroenterology, science and art of, 1–2
 gastrointestinal complications, 385
 gastrointestinal hormones, as growth factors, 173
 gastrointestinal motility, 182
 gastrointestinal physiology, effect of immune activation and inflammation on, 182–6
 gastrointestinal tract
 biopsies of, 249–50
 upper in CD, 231–3
 gastrojejunostomy, 485, 489
 gatifloxacin, 622
 Geboes index, 330
 gelatinase B (MMP-9), 175
 GeneChips, 285
 Affymetrix, 285–7
 General Medical Council (GMC), UK, 706
 genes
 anti-angiogenic expression of, 163–4
 APC, 511, 540
 ATG, 284
 ATG16L1, 5, 20–2, 132, 284
 bcl-2, 540
 and carcinogenesis, 508–10
 CARD4, 19
 CARD15, 5, 17, 21, 283–4
 structure of, 18
 CD1, 104
 CDH1, 513
 DCC, 511–12
 defensin 5, 286
 DLG5, 18, 21
 DPC4, 511–12
 EYA4, 513
 hMLH1, 512–13
 hMSH2, 512
 HPP1/TPEF, 513
 for IBD, 18
 IBD5, 19, 21, 284
 IL23R, 19–21, 284
 invasion, 647
 IRGM, 5, 20–2
 mdr1a, 27–8
 MGMT, 513
 MIC, 532
 MICA, 555, 557
 mismatch repair (MMR), 512–13
 MMPs, 286
 NOD1, 19, 22
 NOD2, 5, 16–17, 21, 27, 283–4
 OCTN1-2, 19, 22
 p14, 513
 p16, 513, 540
 p53, 511–13, 515, 540
 Phex, 666, 699
 polymorphism in, FCGR3A-158, 285
 pro-opiomelanocortin (POMC), 342
 prothrombin, 202
 PTGER4, 20–2
 REG, 286
 S100, 286
 sequencing of, 1
 Smad, 85
 Smad-4, 540
 TGF β R2, 513
 TLR, 19, 21
 TNFSF15, 5, 7, 20
 transcription by GR
 transactivation of, 341, 341
 transrepression of, 341–3, 342
 tumor suppressor, loss of, 511–12
 VDR, 667
 genetic factors and IBD, 44
 genetic manipulation, 25
 genetic markers, 284–5
 genetic research, 713
 genetic risk factors, 1
 genetics
 advances in UC, 20–1
 and biological pathways, 20
 and clinical practice, 21
 of IBD, 16–24
 and inheritance, 568
 study methodologies of, 16–17
 Gengraf, 423, 434
 genome, 713
 genome-wide association studies (GWAS), 5, 7, 18, 19
 genomic instability, 510
 genomics, 16–24, 279–91
 functional, 285–8
 genotyping, 1
 germinated barley foodstuff (GBF), 695, 697
 modes of action, 699
 GETAID study, 475, 477, 499–500, 503
Giardia lamblia, 107, 586
 glaucoma, 423
 gliadin, 102
 glial cells, 185
 glibenclamide, in herbal remedies, 700, 709
 gliotoxin, 349, 351
 glucagon, 235
 glucagon-like peptide-2 (GLP-2), 173, 176
 glucocorticoid receptors (GR), 338
 and glucocorticoid action, 338–40
 isoforms of, 338
 GR α , 338, 340
 GR β , 338, 343
 human (hGR), 338–9

726 Index

- glucocorticoid receptors (GR), (*Cont.*)
mechanisms of action, 339
molecular, 341–3
molecular structure of, 340–1, 340
regulation of expression, 343
response elements (GREs), 340–1
transactivation of gene transcription, 341
- glucocorticoids
anti-inflammatory mechanisms of, 345
and glucocorticoid receptors, 338–40
modulating elements (GME), 343
multi-site targeted therapy by, 338–47
non-response to, 339–40, 343–4
- glucosaminoglycans, 172
- glucose-6-phosphate dehydrogenase, 200
- glutamine, 171, 699
enemas, 463
- glutathione, 405
peroxidase, 699
- glycocalyx, 54, 102
mucinous, 97
- glycolipids, 137
- glycoproteins, 106, 119, 172
gp180, 27
- glycosylphosphatidylinositol, 104
- goblet cells, 30, 54, 106
- gold salts, 298
- golimumab, 425
- gonorrhea, 294, 296, 557, 586
- good practice, in decision-making models, 313
- gout, 133, 557
- graft-versus-host disease (GvHD), 21
- granulocyte macrophage colony-stimulating factor (GM-CSF), 142, 203
- granulocytes, 107
- granulomas, 144, 233, 248, 254, 260, 377, 543–4, 647
caseating, 647
cryptolytic, 248
epithelioid, 233
non-caseating, 256
- granulomatosis, oro-facial, 405
- Granustix, 419
- growth factors, 162–3
in colitis animal models, 83–4
epidermal (EGF), 171–2
fibroblast (FGF), 172
basic (bFGF), 173
gastrointestinal hormones as, 173
insulin-like (IGFs), 173–4
keratinocyte (KGF), 172–3
peptide, 171
vascular endothelial (VEGF), 172
see also transforming growth factors
- growth failure
approach to, 593
in pediatric patients, 591
- growth hormone, 177
- growth retardation, 445, 585
- guanylhydrazone, 382
- Guillain-Barré syndrome, 648
- gum arabic, 409
- gut
epithelium as defense layer, 53–5
physiological systems of, 182
and mucosal immune system, 182–94
sensory-motor apparatus and inflammation, 189–91
vasculature of, 610–11
- gut-associated lymphoid tissue (GALT), 52–3, 71, 92, 100–1
and HIV infection, 659–60
inductive sites of, 53–7
and inflammation, 158–9
- halides, 107
- hand washing, 637
- hand-assisted laparoscopic surgery (HALS), 445, 450
- haplotypes, 532
- HapMap, 17, 532
- haptens, 136, 404
- haptoglobin, 200
- Hartmann's pouch, 298, 614
- Harvey-Bradshaw index (HBI), 326–7, 327, 673
- Hassons technique, 451
- health education, and natural history of UC, 223
- healthcare
costs and disease management (DM), 308–9
effectiveness of implementation strategies, 315
need of management solution for, 304–5
- heartburn, 232
- heat shock protein 90 (hsp90), 340–1, 343–4
- Heineke-Mickulitz stricturoplasty, 486–7, 487
- Helicobacter*, 44, 102
hepaticus, 93, 121, 134–5, 142
pylori, 86–7, 94, 108, 187, 232, 256, 587, 645
- helminths, 109, 136–8, 647, 652
- hematochezia, 230, 297, 614, 662
- hematology, and intestinal inflammation, 197–205
- hematopoiesis, 145
- hematopoietin, 119
- hemochromatosis, 648
- hemoglobin, 198–9
- hemojuvelin, 198
- hemolysins, 646
- hemolysis, 200
- hemolytic-uremic syndrome, 295, 643, 646, 648, 653
- hemophilia, 165, 202
- hemorrhage, 233, 297
variceal, 542
- hemostasis, and inflammation, 165
- Henoch-Schönlein purpura, 299, 565
- heparin, 167, 172, 427, 710
sulfate proteoglycans, 175
- heparin-antithrombin system, 164
- hepatobiliary disorders, and IBD, 529
- hepatitis, 258, 426, 681
autoimmune (AIH), 259, 532, 542, 625
chronic, 529
drug-induced, 544
hepatitis B, 385, 684–5, 700
hepatitis C, 542, 700
and infliximab, 544
interface, 542
- hepatobiliary complications, 385
- hepatobiliary disease, 258
- hepatocyte growth factor (HGF), 173
- hepatocytes, 104, 133, 140
- hepatomegaly, 258
- hepatosplenic T cell lymphoma (HSTCL), 204, 477, 590, 679
- hepatosplenomegaly, 204, 534
- hepcidin, 197–8
- herbal therapies, 695–8
interactions with drugs, 700
modes of action, 698–9
- hernia, parastomal, 456
- herpes simplex virus (HSV), 107, 255, 292, 294–5, 384, 680
type II, 297
- herpes zoster, 384
- heterogeneity
classical clinical, 4–5
genetic, 5–6
harnessing of, 7
of IBD, 3–8
laboratory, 5
of treatment responses, 6–7
- heterozygosity, loss of (LOH), 511–12
- hindgut, 259–60
colonoscopy, 261
endoscopy, 261
disease activity monitoring by, 261–2
ileoscopy, 261
- histamine, 183–4
- histology, in infectious colitis, 294–5, 294, 652
- histones, H1, 279
- histopathology, 245
- histoplasmosis, 297, 384, 684
- HIV/AIDS, 108, 145, 292, 295, 533, 625, 645, 649
and CD, 661, 661
epidemiology of, 658–9
and IBD, 658–64
reported cases, 660–2
mucosal immunopathogenesis of, 659–60
natural history of, 658–9
signs of, 650
treatment of, 658–9
and UC, 661, 661
- Hodgkin's lymphoma, 203–4
- homeostasis
bacterial, host response to, 92–118
chemokines in, 119–56
cytokines in, 119–56, 120
mucosal, 52–63, 119–56
role of Tregs in, 58–9
- homeostatic proliferation, 142
- ⁷⁵Se-homocholeic acid taurine test (⁷⁵Se-HCAT), 602
- hormone deficiency, 591, 593
- hormone replacement therapy (HRT), 541
- hospitalization, 433
- host immune response, 1
to bacterial homeostasis, 92–118
- host-microbe interface, 1, 392
- host-microbiota relationship, 25
- hosts, immunocompromised, 204
- human anti-chimeric antibodies (HACAs), 424–5
- human genome, 1, 17
- human immunodeficiency virus (HIV) see HIV/AIDS
- human leukocyte antigen (HLA), 19, 531, 571
and arthropathy in IBD, 555
haplotypes, 531

- HLA-B27, 554–7, 648
- HLA-B44, 555
- human papilloma virus (HPV), 680–1
 - vaccine, 569
- humans
 - and CXCR4, 145
 - cytokines and chemokines in IBD, 127–30
 - and GM-CSF, 142
 - and IFN- γ , 126
 - and IL-1 α , 132–3
 - and IL-2, 132
 - and IL-4, 136–7
 - and IL-5, 137
 - and IL-6, 133–4
 - and IL-10, 139
 - and IL-11, 141
 - and IL-13, 137
 - and IL-17, 136
 - and IL-18, 126
 - and IL-21, 141
 - and IL-22, 140
 - and IL-23, 135
 - and IL-32, 142
 - and MCP-1, 143
 - NK-T cells in, 105
 - and TGF β , 140
 - and TL1A, 134
 - and TNF α , 130
- Humira, 678
 - see also adalimumab
- Hungarian Case Control Surveillance, 570, 572
- hyaluronic acid, 66
 - receptors, 178
- hybridoma, 363
- hydrocolonic sonography, 268
- hydrocortisone, 216, 420, 422, 425, 433
- hydrogen peroxide, and fistula detection, 268
- hydrogen sulfide, 96, 409
- hydronephrosis, 237
- hydroxychloroquine, 429
- 5-hydroxytryptamine (5-HT), 182
- hygiene hypothesis, 10, 44
- hyperalbuminemia, 534
- hyperalgesia, 185–6
- hypercoagulability, 200–1
 - causes in IBD, 203
- hyperemia, 167, 626
- hypereosinophilia, 299
- hyperhomocysteinemia, 202, 237
- hyperkalemia, 575
- hyperparathyroidism, 672
- hyperphagia, 410
- hyperplasia, 521
 - colonic, 38
 - epithelial, 35, 138
 - gingival, 233
 - goblet cell, 138
 - lymphoid, 40
 - mucosal, 37
- hypersensitivity pneumonitis, 681
- hypertension, 423
- hypnotherapy, 698
 - mode of action, 700
- hypoalbuminemia, 183, 586–7, 628–9, 652
- hypoaldosteronism, 410
- hypcholesterolemia, 434
- hypoferremia, 197–8
- hypokalemia, 636
- hypomagnesemia, 410
- hypoplasia, thymic medullary, 37
- hypotension, 297
- hypothalamic–pituitary–adrenal axis, 699
- hypothalamus, 196
- hypoxanthine–aminopterin–thymidine (HAT), 363
- hypoxia, 101, 167
- ibandronate, 671
- IBD genome, 1
- ileal disease, 21, 230–1
- ileal pouch, 4
 - CD of, 461, 464–5
 - creation of, 447–8
 - laparoscopic, 450
 - disorders of, 461–8
 - failure of, 281
 - fistula, 281
 - late complications, 453–4
 - revision of, 454
 - size of, 448
 - surgery, 281, 447–50
 - reach to pelvic floor, 449
 - and vaginal delivery, 572
 - valve slippage in, 453–4
 - see also J-pouch; K-pouch; pelvic pouch; S-pouch
- ileal pouch anal anastomosis (IPAA), 281, 445–52, 461
 - and CD, 490–1
 - and cuffitis, 463–4
 - laparoscopic, 451
 - in pediatric patients, 596
- ileitis, 43, 130, 137
 - backwash, 461, 464
 - in UC, 250, 260
 - CD, 464
 - NSAID-induced, 464
 - pseudomembranous, 626
 - “string sign” of, 235
 - terminal, 295
- ileoanal pouch, 220, 250
- ileocecal disease, preventing relapse of, 474–5
- ileocolonic disease, 230
- ileocolonoscopy, 266, 270, 652
- ileoscopy, hindgut, 261
- ileostomy, 220, 484
 - continent, 445, 452–4
 - diverting, 444, 446, 456–7, 457
 - end, 444–5, 454–5
 - loop, 493
- ileum, 34, 94, 134
 - comb sign, 273
 - distal, 179, 230
 - mural thickening, 269, 272
 - resection of, 198
 - terminal, 43, 72, 233, 257
 - vasa recta, engorgement of, 270
- ilodecakin, 378
- imaging
 - abdominal, 652
 - cross-sectional, 652
- in IBD, 266–78
- imidazoquinolines, 70
- imiquimod (R-837), 70
- immune activation, effect on gastrointestinal
 - physiology, 182–6
- immune cascade, and PSC, 533
- immune cells
 - cross-talk with epithelial cells, 107–10
 - types of, 98–101
- immune defects, multiple, 45
- immune factors, and *C. difficile* host defense, 623–4
- immune markers, serologic, 279–80
- immune modifier medications, 423–4
- immune reconstitution inflammatory syndrome (IRIS), 660–1
- immune regulation, 45
 - deficient, 37–41, 37
- immune response, 7, 97
 - dysregulated, 4, 25
 - epithelial cells in, 186–8
 - focus on, 3–4
 - gastrointestinal
 - effector site of, 57–9
 - inductive site of, 53–7
 - neuro-motor apparatus in, 188–9
- immune suppression, and infections, 383
- immune system
 - adaptive, 52
 - and aberrant T cell development or activation, 35–7, 35
 - and effector cell function, 33–5, 33
 - humoral, 623
- innate, 25–6, 52, 64–81
 - cells of, 64
 - epithelial models of, 27–30, 28
 - myeloid models of, 30–3
 - overview of, 65–6
- intestinal, 52, 53
 - mucosal, 3–4
 - cell types in, 53
 - and commensal bacteria, 60–1
 - effector sites of, 52
 - and gut physiological systems, 182–94
 - inductive sites of, 52–7
- immunity
 - adaptive, 65, 72–3, 82–91
- innate, 65, 72–3
 - extrinsic barriers in, 106–7
 - intrinsic barriers in, 106
- linking IBD susceptibility and commensal
 - bacteria, 73–5
 - and NF- κ B activation, 349–50
 - and pathogenesis of IBD, 64–81
 - and T cell activation, 66
 - throughout intestinal mucosa, 105–10
- immunity-related guanosine triphosphatase
 - family M (IRGM), 20
- immunodeficiency, 587
- immunogenicity, 382–3
- immunoglobulins
 - IgA, 55–6, 59, 98–101, 187, 280, 282–3
 - induction of, 70–1
 - IgE, 59–60
 - IgG, 32, 59, 98, 280, 282–3, 624

728 Index

- IgM, 59, 98, 187
 - intravenous (IVIG), 634
 - receptors, 187
- immunologic factors, and IBD, 44–5
- immunologic hypothesis, 25
- immunomodulators, 471, 475–7
 - benefits and risks of, 680–1
 - in pediatric patients, 588–9
 - and pregnancy, 574
 - risks vs. benefits of, 678–92
 - toxicity of, 680
- immunoproteasome, 104
- immunosuppressants
 - and dysplasia, 569
 - and pouchitis, 463
 - and PSC, 538–9
 - T lymphocyte, 589–90
- immunosuppression, 40, 292
 - and infectious colitis, 293
 - and liver transplants, 541
 - and lymphomas, 204, 682
 - and NF-B, 350–1
 - and postoperative recurrence, 502
 - and vaccinations, 576
 - and viral infections, 684
- immunosuppressive therapy, 203, 239
- Imodium, 632
- impotence, postoperative, 447
- Imuran, 423
- incisions
 - midline, 446
 - Pfannenstiel, 446, 450
- inclusion bodies (owl's eye), 652
- incontinence, fecal, 184
- incontinentia pigmenti, 349
- indomethacin, 167
- induction trials, 325
- induration, 490
- infections, 101, 383–4
 - bacterial, 384
 - fungal, 384
 - nosocomial, 623
 - opportunistic, 478
 - of urinary tract, 384
 - viral, 384
- infectious agents, in colitis, 295–7
- infectious colitis *see* colitis, infectious
- infertility, 568–9
- inflammation, 40
 - action of vagus nerve on, 188
 - acute response to, 195
 - angiotensin in, 166–7
 - of appendiceal orifice, 218
 - and autonomic nervous system, 186
 - biological markers of, 279–84
 - and CAC rates, 508–9
 - and central nervous system, 186
 - cytokine pathways in gut, 82–91
 - defective dilation and perfusion in, 167
 - definition of, 157
 - effect on epithelial cells, 183–4
 - effect on gastrointestinal physiology, 182–6
 - and efferent nerves, 185
 - endothelin in, 166–7
 - and entero-endocrine cells (EECs), 186
 - and enteroglia, 185
 - extraintestinal consequences of, 195–211
 - and gut sensory-motor apparatus, 184–6
 - and hemostasis, 165
 - and interstitial cells of Cajal, 186
 - intestinal, 158, 609
 - hematologic consequences of, 197–205
 - low-grade (physiological), 52
 - lymphocyte trafficking in, 157–60
 - microvascular blood flow in, 166–7
 - modulation by physiological systems, 186–9
 - ocular, 559
 - parasite-induced, 183
 - pro-inflammatory and angiogenic mediators in, 162
 - regulated by TGFβ, 84–7
 - role of SMAD7 in control, 87
 - role of vasculature in, 157–69
 - and sensory nerves, 185–6
 - severity and risk of CRC, 520
 - signs of on CTE, 269
 - and smooth muscle contraction, 184–5
 - superficial, 4
 - systemic response to, 195
 - thromboxane in, 166–7
 - transmural, 4
- inflammatory bowel disease
 - age and risk of CRC, 520
 - and amyloidosis, 204–5
 - and angiogenesis, 161–2
 - angiogenic mediators in, 162–3
 - anti-angiogenic gene expression in, 163–4
 - antibiotic therapy of, 393–6
 - the appendix in, 249
 - and arthritis, 553–4
 - bone fracture risk in, 668–70
 - and bone metabolism, 665–77
 - and bone mineral density (BMD), 667–8
 - and bowel wall thickness, 267
 - C. difficile* infection in, 629
 - cancer surveillance in, 518–27
 - causes of hypercoagulability in, 203
 - cellular mechanisms of glucocorticoid action in, 344–6
 - chronic, 250
 - classification of, 4, 288
 - and colorectal cancer, 262, 520
 - cutaneous manifestations of, 563–6, 563
 - cytokine-directed therapies for, 131
 - cytokines and chemokines in, 127–30
 - definition of, 92
 - demographics of, 13–14
 - depression in, 189
 - dermatologic conditions in, 562–7
 - dietary factors in, 402–3
 - differential diagnosis of, 254, 662
 - differentiation from non-IBD, 280–1
 - disease activity monitoring in, 261–2
 - and disease management, 303–22
 - duration and risk of CRC, 519
 - Dysplasia Morphology Study Group, 521
 - and environmental factors, 43–4
 - epidemiology of, 9–15
 - adult studies, 12
 - child studies, 13
- European, 11
- evaluation of anemia in, 200
- extra-intestinal manifestations of, 4, 650
- and eye conditions, 553–61
- fertility in
- fibrostenosing (FS), 282–3
- and functional genomics, 285–8
- future research on, 7
- genetic susceptibility to, 44, 73–5, 284–5
- genetics of, 16–24, 44
- genome, 1
 - identified genes, 18
- glucocorticoid therapy in, 346–7
- hepatobiliary complications of, 528, 529
- heterogeneity of, 3–8
 - and animal models, 7
- and HIV, 658–64
 - reported cases, 660–2
 - treatment of, 661–2
- imaging in, 266–78
- and immunologic factors, 44–5
- in vivo models of, 25–51
- inflammation of sensory nerves in, 185–6
- inflammatory and hemostatic mechanisms in, 164–6
- internal-penetrating (IP), 282–3
- interplay among components of, 43
- and intestinal infection, 654–5
- and joint conditions, 553–61
- legal pitfalls in treatment of, 705–12
- and liver disease, 528–52
- long-term management of patients with, 706–7
- mechanisms of bacteria-driven, 95–7, 96
- medications used in, 573
- and metabolic syndrome, 205
- microbiota in, 392–3
- and microcirculation, 609–18
- microvasculature in, 612–13
- most common form of, 10–12
- murine models of, 122–6
- NF-κB activation in, 349
 - inhibition in therapy, 348–51
- non-targeted therapeutics for, 337–59
- nurse specialist, 706–7
- nutritional deficiencies in, 409–10
- ocular manifestations of, 559–60
- orocutaneous manifestations of, 562–63
- outcome measures of trials, 325–30
- pathogenesis of, 360–2
 - and innate immunity, 64–81
 - innate/adaptive immunity links, 72–3
- pediatric, 10, 12–13, 283, 584–600
 - clinical presentations of, 584–5
 - diagnostic approaches to, 585–7
 - disease activity markers in, 587
 - epidemiology of, 584
 - malnutrition in, 591–4
 - psychosocial functioning in, 594–5
 - surgical considerations in, 595–6, 596
 - therapeutic approaches to, 587–90
 - transition to adult care from, 596–7
- peptide growth factor therapy for, 176–8, 177
- phenotypic stratification of, 282–4
- placebo response in, 331
- polypoid dysplasia in, 515

- practical pathology in patient management, 245–53
- predictor of disease susceptibility, 284
- predictor of response to therapy, 284
- pregnancy in, 568–83
- probiotics in, 396–8
- quality of life in, 313, 330
- questionnaire (IBDQ), 330, 397, 698
- regulation of GR action in, 343–4
- regulation of SMAD7 in, 86–7
- relationship with PSC, 535–7
- relationship to microbial populations, 95
- replicated linkage regions for, 17
- research on, 713–14
- role of endoscopy in diagnosis and treatment, 254–65
- role of nutrition in evaluation and treatment, 402–14
- role of stress in, 189
- science and art of, 1–2
- site-specific therapies for, 361, 369–82
- Smad signaling in, 86
- spontaneous, 41–3
- susceptibility genes in, 17–19
- symptoms of, 261
- in upper gastrointestinal tract, 254
- targeted treatments for, 360–91
- therapeutic manipulation of microbiota, 392–401
- therapy for
- communicating risk in, 685–8
- and cutaneous manifestations, 565–6
- risks vs. benefits of, 678–92
- and thrombosis, 164–6, 201
- treatment of, 713–14
- treatment of osteoporosis in, 669–703
- use of CAM in, 694–5, 694
- inflammatory cascade, 362
- inflammatory responses, to enteropathogens, 647
- infliximab, 188, 204–5, 216, 256, 268, 285, 360, 424–5
- in acute colitis, 709–10
- antibodies to (ATIs), 424–5
- and arthritis, 558–9
- and CD, 472–3, 475–8
- and cholestasis, 544
- in combination with natalizumab, 381
- and conception, 578
- cost-effectiveness of, 310–11, 317, 386
- and cutaneous manifestations, 565–6
- and dysplasia, 569
- effects on surgery, 485
- efficacy and safety of, 371–3
- and the elderly, 234
- and fistulas, 492
- and gastrointestinal complications, 385
- and heart failure, 384
- and hepatitis, 544
- and hepatobiliary complications, 385
- and high antigen load, 367
- and HIV patients, 662
- and immune responses, 284
- and lymphomas, 681
- and malignancy, 385
- mechanism of action of, 373–4
- medico-legal issues, 708–9
- and multiple sclerosis, 684
- and neurologic events, 385
- and ocular inflammation, 560
- and osteoporosis, 670–1
- in pediatric patients, 590, 596, 683
- pharmacokinetics of, 374
- and postoperative recurrence, 504–5
- and pouchitis, 463
- and pregnancy, 575–7, 576
- and pyoderma gangrenosum, 564–5
- and pyostomatitis vegetans, 563
- rescue therapy with, 434
- safety issues, 678, 681–3, 685
- side effects of, 425, 682
- therapy, 432–3
- and tuberculosis, 383, 683
- Infliximab Safety Database, 576
- information bias, 333
- inheritance, and genetics, 568
- insulin, 205
- insulin-like growth factors (IGFs), 173–4
- integrated care (IC), 303, 305
- integrins, 178, 379–80, 611
- $\alpha 4$, 380
- $\alpha 4\beta 1$, 380–1
- $\alpha 4\beta 7$, 57, 380–1
- $\alpha L\beta 2$, 381
- VLA4, 57
- intercellular cell adhesion molecule-1 (ICAM-1), 61, 611–12
- interferons, 119, 198–9
- IFN- α , 426
- IFN- γ , 7, 26, 28, 32, 34, 55, 126, 130, 183
- inducing factor (IGIF), 121
- inhibitor of, 377
- INF- β -1a, 426
- interleukins, 119
- IL-1, 5, 26–8, 35, 39, 108
- biological effects of, 196
- family, 195
- systemic effects of, 197
- IL-1-F4, 121
- IL-1 β , 5, 30, 132–3, 666
- IL-2, 26, 34, 39–40, 99, 130–2, 376, 426, 589
- IL-2R, inhibitors of, 376
- IL-4, 26, 32–4, 36, 55, 136–7
- IL-5, 26, 32–3, 55, 137
- IL-6, 5, 26–8, 30, 33, 39, 89, 108, 133–4, 375–6, 667, 700
- biological effects of, 196
- and bone remodeling, 667
- family, 196
- systemic effects of, 197
- and Th17, 133
- IL-6R, inhibitor of, 375–6
- IL-7, 34, 108, 142–3, 187
- IL-8, 35, 145, 171, 187, 625, 647, 699
- IL-10, 26, 32–9, 55, 59, 108, 138–9, 377–8, 396–7, 396
- pathway to colitis, 39
- and postoperative recurrence, 504
- recombinant human (rhuIL-10), 378, 426
- IL-10R, 377
- IL-11, 140–1, 378
- recombinant human (rhuIL-11), 378
- IL-12, 28, 31–3, 35, 38, 42, 72–3, 121, 376–7
- inhibitors of, 376–7
- p40 subunit of, 134–5
- IL-13, 26, 33, 36, 55, 98, 137, 700
- IL-15, 108, 605
- IL-17, 5, 26, 32–4, 39, 42, 72, 89, 135–6, 174
- IL-17E, 138
- IL-18, 121, 126
- IL-21, 26, 82, 141
- control of MIP-3 production, 88
- and matrix metalloprotease secretion, 88–9
- multiple effects in gut, 89
- role in CD, 87–9
- and Th17 cells, 89
- IL-22, 140
- IL-23, 5, 31–2, 38, 42, 72–3, 121, 134–5, 174, 377
- p19 subunit of, 134–5
- p40 subunit of, 134–5
- IL-25, 33, 138
- IL-27, 141
- p28 subunit of, 141
- IL-32, 142
- IL-35, 141
- International Organization for the Study of IBD (IOIBD), 272
- International Patient Decision Aids Standards (IPDAS), 687
- International Society for Clinical Densitometry, 672
- interstitial cells of Cajal (ICCs), 184
- and inflammation, 186
- intestinal epithelial cells *see* epithelial cells, intestinal (IECs)
- intestinal failure, 410–11
- intestinal microbiota *see* microbiota, intestinal
- intestinal mucosa *see* mucosa, intestinal
- intestinal trefoil factor (ITF), 29, 106
- intestine, 647
- large, 174
- common bacteria in, 94
- protection from injury, 171
- small, 140, 172, 174
- microbiota of, 94
- TLR2 signaling in, 69
- TLR4 signaling in, 69
- intimin, 646
- receptor, 646
- intraductal ultrasonography (IDUS), 259, 540
- intussusception, 295
- iohexol, 269
- ion transport, in epithelial cells, 183–4
- irinotecan, 298
- iritis, 559
- iron, 230
- deficiency of, 409, 563, 593
- dextran, 198–9, 563
- overload of, 648
- oxide, 272
- saccharate, 198
- sucrose, 409, 563
- sulfate, 409
- irritable bowel syndrome (IBS), 186, 228, 317, 326, 328, 465
- irritable pouch syndrome (IPS), 461, 465

730 Index

- ischemia, 5, 167, 629, 652
 rectal, 297
 ischemic colitis *see* colitis, ischemic
 Isis 2302, 425
 isoniazid, 383, 653
 isotretinoin, 298
- J-pouch, 448
 creation of, 448
 jaundice, 385
 obstructive, 259
 and PSC, 258, 534–5
 JC polyoma virus, 384, 425, 613
 jejunostomy, 410
 high-output, 410–11
 jejunum, 72, 94, 231
 proximal, 257
 jejunum–colon, 410
Jian Pi Ling, 695
 joints
 conditions associated with IBD, 553–61
 disease of, 34
 metacarpophalangeal, 553
 sacroiliac, 557
- K-pouch, 452–4
 construction of, 453
 Kaplan–Meier survival curves, 556
 Kaposi’s sarcoma, 426, 659, 661
 Katayama fever, 645, 649
 keratin, 29
 keratinocyte growth factors (KGFs), 172–3
 KGF-1, 426
 KGF-2, 173, 426
 keratinocytes, 38, 140
 kernicterus, 572
 6-ketoprostaglandin F1 α , 108
 kidney, 134, 140, 187
 stones, 237
 killer activating receptors (KARs), 100
 killer inhibitory receptors (KIRs), 100
 kinases
 cyclin-dependent, 339
 mitogen-activated protein (MAPKs), 339
- Klebsiella*, 556
oxytoca, 645
pneumoniae, 134
 Kraske position, 454
Kui jie qing, 695
- labia, 235
 fissures of, 255
 labor and delivery, 572
 Lachnospiraceae, 69
 lactobacilli, 406, 623
 fecal, 393
 lyophilized, 429, 462
Lactobacillus, 93, 95, 395, 398, 462, 636
acidophilus, 398, 429
casei, 429
delbrueckii subsp. *bulgaricus*, 429
johnsonii, 503
plantarum, 429
 and postoperative recurrence, 503–4
rhamnosus GG, 398, 636
- Lactococcus*, 44, 378
lactis, 139, 396
 lactoferrin, 107
 fecal, 267, 587
 lactose intolerance, 409, 465
 lactulose, 406
 lamellipodia, 170, 178
 lamina propria, 27, 38, 56, 646
 cell populations of, 175
 lymphocytes of (LPLs), 57, 99–100
 mononuclear cells (LPMC), 86
 T cells of, 57–8
 laminaribioside, 72, 280–1
 laminin, 175, 178
 lamivudine, 385
 lansoprazole, 602
 laparoscopy, 445, 484–5
 laparotomy, 233, 257, 446
 latex agglutination assay, 631
 lectins, 105, 646
Leishmania
donovani, 141
major, 141
 lenercept, 385, 684
 lesions
 of anal canal, 491
 colonic, 257
 dysplastic, 524
 inflammatory, 498
 petechial, 299
 raised, 524
 rectal, 298
 skip, 249
 summit, 295, 626, 652
 tattooing of, 263
 volcano, 626, 652
 leucine-rich-repeat (LRR) domain, 17
 leucopenia, 476, 680–1
 leukemia, 203, 299
 acute lymphoblastic, 204
 acute myeloid, 204
 leukocytes, 108, 143, 611
 fecal, 627–8
 inhibitors of adhesion, 379–82
 labeled, 273
 model of extravasation, 380
 polymorph, and contractility / , 185
 rolling of, 165
 leukocytosis, 202–3, 628–9
 leukoencephalopathy, 238
 leukopenia, 432, 589
 leukotriene inhibitors, 428
 leukotrienes, 184
 B4, 427–8, 592–3
 B5, 593
 levamisole, 428
 levofloxacin, and pregnancy, 573
 Lialda, 417, 420
 Lichtiger index, 328
 lidocaine, 428, 563
 ligands
 for activated factor of nuclear factor kappa B
 (RANKL), 665–6
 CD1d, 104–5
 likelihood ratios (LR), 282
- linezolid, 632
 linkage disequilibrium (LD), 19, 532
 linoleic acids, 347
 lip swelling, 233
 lipase, 238
 lipids, 108
 lipoarabinomannan, 66
 lipomas, 247
 lipopolysaccharide (LPS), 66, 533
 and role of TLR4, 67–9, 509
 lipoteichoic acid, 66
Listeria monocytogenes, 20, 71, 106–7
 listeriosis, 384, 684
 lithotomy, 454
 position, 451
 litigation, medical, 705–6
 liver, 133, 173, 258, 647, 649
 abscess, 544
 disease
 and IBD, 528–52
 prevalence of, 528–9
 failure, 684
 fatty, 542–3, 542
 and IL-18, 126
 orthotopic transplantation (OLT), 258–9, 540–1,
 540
 locus of enterocyte effacement (LEE), 646
 Lomotil, 632
 loperamide, 411, 433, 632, 653
 lung, 138, 187
 lupus anticoagulant, 201
 lupus glomerulonephritis, 379
 lupus syndrome, 383
 drug-induced, 684
 lymph nodes, 53
 mesenteric, 31, 36, 53, 70
 and induction of inflammation, 158–9
 and oral tolerance, 60
 peripheral, 159
 lymphadenopathy, 39, 649
 mesenteric, 267
 lymphocytes, 29, 33–4, 36, 130, 132–3, 142, 184,
 603–4
 cellular determinants for trafficking, 161
 and contractility, 185
 cytotoxic T (CTLs), 104
 and epithelial cells, 187
 and glucocorticoids, 344–5
 intraepithelial (IELs), 54, 100, 107, 142, 173,
 603–4
 of lamina propria (LPLs), 57, 99–100
 mucosal, 28, 38
 migration of, 57
 and PSC, 533
 regulation by luminal microbiota, 100–1
 response in Peyer’s patches, 55–6
 trafficking in chronic inflammation, 157–60
 lymphocytosis, 603
 lymphogranuloma venereum (LGV), 293, 586, 658,
 662
 lymphoid aggregates, 246
 basal, 294
 lymphoid follicles, 52–3, 97, 246
 isolated (ILFs), 99
 lymphomas, 197, 203–4, 230, 299, 385, 476

- B-cell, 204
- brain, 203
- hepatosplenic T cell (HSTCL), 204, 477, 590, 679, 682–3
- Hodgkin's, 203–4
- and infliximab, 681
- non-Hodgkin's (NHL), 203, 385, 423, 680–2
- risk of, 680–2
- lymphopenia, 36–7, 659–61
- lymphotoxin, 54
- lysophospholipids, 69
- lysozymes, 54, 107
- M cells, 54–5, 97, 102, 187, 646
- macrolides, 622
- macrophage inflammatory proteins (MIPs)
 - MIP-2, 621
 - MIP-3, 56, 88
- macrophages, 38, 65, 107, 121, 130, 132–3
- and glucocorticoids, 345–6
- immunological properties of, 56
- intestinal, 56
- magnesium, 410
- magnetic resonance cholangiopancreatography (MRCP), 258–9, 534
- magnetic resonance enteroclysis, 266, 271–3
- magnetic resonance enterography (MRE), 266–78
- magnetic resonance imaging (MRI), 540, 586
- maintenance trials, 325
- major histocompatibility complex (MHC), 19, 531
 - class I molecules
 - HLA-A2, 36, 54, 97, 101, 531
 - HLA-B7, 36
 - HLA-B27, 36
 - class II molecules, 36, 39, 54, 56, 97, 101, 186–7
 - processing by IECs, 102–4
- malaise, 195
- malignancies, 384–5
 - colorectal, 258
 - hematologic, 203–4
 - rectal, 450
- malnutrition, 230, 409
 - assessment and management of, 591–4
 - in pediatric patients, 591
- managed health care, 303, 305
- masking (blinding), 324
- mast cells, 107, 183–4, 346
 - and contractility, 185
 - mucosal, 187
 - and PSC, 533
- mastic, 697
- Mathematical Model for End Stage Liver Disease (MELD), 535
- matrix metalloproteinase secretion, and IL-21, 88–9
- matrix metalloproteinases (MMPs), 88, 141, 175, 532, 604
- matrix molecules, 163
- Mayo Clinic PSC risk score, 535
- Mayo Practice Guideline Score (MPGS), 251, 313, 329, 418
- MD-2 molecule, 68
- meat, 403
- Medco, 304–5
- Medicaid, 310–11
- medical records, electronic, 308–9, 315–16
- Medicare, 308–11
- medications
 - during pregnancy, 572–7
 - immune modifier, 423–4
 - for pediatric patients, 588
 - used in IBD, 573
- medico-legal risk, 705–12
- MedWatch program, 333, 678–9, 683
- megacolon, 433
- megakaryocytes, 36
- megaloblastosis, 198
- melanoma, 426
- Melkersson–Rosenthal syndrome, 233
- memory marker CD45RO, 99–100
- men, fertility and sexual function of, 569–70
- meningitis, 648
- 6-mercaptopurine, 199, 203–4, 238, 255, 360, 423–5, 432
 - and CD, 471–2, 474–5, 477, 680
 - cessation of, 476
 - and colonic disease, 472
 - and conception, 577–8
 - and IBD, 509
 - medico-legal issues, 708
 - metabolic pathways of, 589
 - and microscopic colitis, 605
 - in pediatric patients, 588–90, 592
 - and postoperative recurrence, 502–3
 - and pouchitis, 463
 - and pregnancy, 574–5
 - safety issues, 678, 680–1
 - side effects of, 423, 680
- mesalamine, 177, 199, 202, 221, 396, 423, 426, 429
 - and conception, 577
 - and CRC, 522
 - and cuffitis, 464
 - delayed-release, 419
 - enemas, 429–31, 463
 - and hospitalization, 433
 - and IBD, 509
 - multi-matrix system (MMX), 420
 - oral, 417, 419–20, 429–32
 - pellets, 419
 - and postoperative recurrence, 501–3
 - and pregnancy, 572, 576
 - rectal, 417, 419–20, 422, 431–2
 - and SCAD, 614–15
 - suppositories, 429, 431
 - sustained-release, 419
 - toxicity of, 420
- mesalazine, 177, 697–8
 - and CD, 471–4
 - and hepatitis, 544
 - and IBD, 509
 - and postoperative recurrence, 502–3
- Mesasal, 417
- mesenchyme, 175
- mesenteric lengthening techniques, 449
- mesorectum, 447
- meta-analyses, 333–4
- metabolic syndrome, and IBD, 205
- metalloproteinases, 171
- metallothionein, 287
- metasulfobenzoate, 472
- methicillin, 445
- methotrexate, 199, 237, 317, 360, 410, 423, 425
 - and aphthous stomatitis, 563
 - and arthritis, 558–9
 - and *C. difficile* diarrhea, 623
 - and CD, 474–7, 680
 - and conception, 577
 - embryopathy, 574
 - and hepatotoxicity, 544
 - medico-legal issues, 708
 - in pediatric patients, 589–90
 - and pregnancy, 472, 574
 - and PSC, 538
 - and pyostomatitis vegetans, 563
 - safety issues, 678, 680–1
 - side effects of, 681
- methylation, 513
 - type A, 513
 - type C, 513
- methylcellulose, 269
- methylodopa, 298
- methylene tetrahydrofolate reductase, 202
- 6-methylmercaptopurine (6-MMP), 199, 575, 589
 - and hepatotoxicity, 544
- 6-methylprednisolone, 216, 420, 422, 433
 - and CD, 471
- metronidazole, 31, 238, 287, 393, 395, 427–8, 433
 - and abscesses, 491
 - and *C. difficile* diarrhea, 621, 632–5, 633
 - and CD, 471–2
 - and microscopic colitis, 606
 - in pediatric patients, 588, 590
 - and postoperative recurrence, 503, 505
 - and pouchitis, 462–3
 - and pregnancy, 572–3, 576
 - and PSC, 539
 - side effects of, 393, 395, 632
- Mezavant, 420
 - XL, 420
- mice
 - A20-deficient, 30
 - Apc/min, 69
 - ATG16L1-deficient, 132
 - BALB/c, 121, 136
 - C3H/HeJ/Bir, 41–2, 73, 135–6
 - CCR5-deficient, 144
 - CD1d-deficient, 105
 - CD40 ligand transgenic, 34–5
 - double knockout, 30
 - EBI-3-deficient, 141
 - epithelial NEMO-deficient, 29–30
 - fucosyltransferase transgenic, 37
 - Gi2-deficient, 29, 121, 134
 - IL-2-deficient, 39–40, 121, 131–2, 172, 666
 - IL-2-deficient, 131
 - IL-6-deficient, 133
 - IL-7 transgenic, 34, 142
 - IL-10-deficient, 38–9, 98, 121, 126, 133, 135, 138, 145, 666–7
 - IL-23-deficient, 134
 - induced mutant, 25
 - intestinal trefoil factor-deficient, 29, 98
 - keratin 8-deficient, 29
 - lymphopenic T cell receptor transgenic, 36–7
 - mdr1a*-deficient, 27–8
 - Msh2* knockout, 513

732 Index

- mice (*Cont.*)
Muc2-deficient, 30, 106
 MyD88 knockout, 69
 N-cadherin-dominant negative mutant
 chimeric, 28–9
 NK-1 (SP)-deficient, 621
 NK-T cells in, 105
 NOD2-deficient, 31, 71–2, 132
 nude, 136, 138
 RAG-1-deficient, 126, 130, 135
 RAG-2-deficient, 136, 140
 repopulation of, 93
 SAMP1/Yit, 42–3, 98, 130, 134, 137
 SCID, 138, 140, 186
 senescence accelerated (SAM), 42
 STAT-4 transgenic, 33–4
 STAT3^{-/-}-deficient, 30–1, 73
 TCR α -chain-deficient, 35–6, 132–3, 139–40
 TFF knockout, 174
 Tge26, 121, 126
 TGF β -deficient, 59
 TGF β 1-deficient–41, 509
 TLR4 knockout, 67
 TNF- α 'knock-in' (TNF δ^{ARE}), 34, 121, 126, 134
 transgenic, 134
 epsilon 26, 40
 WASP-deficient, 36, 126, 136–8
 XBP1-deficient, 30
- microarrays, 515
 experiments using, 286–7
- microbial bionetwork, 92–7
- microbial genome, 1
- microbial populations, relationship to IBD, 95
- microbiome, 1, 713
- microbiota
 effects on host, 25
 in IBD, 392–3
 intestinal, 1
 beneficial effects of, 405–6
 luminal, regulation of lymphocytes by, 100–1
 therapeutic manipulation in IBD
- microcirculation, in IBD
- micronutrients, deficiencies in, 410, 473, 593
- microsatellite instability (MSI), 510, 512–14
- microscopic colitides, 247, 298, 601–8
- microscopy, 651
Microsporidia, 586
 microsporidiosis, 659
- microvilli, 106, 646
 intraepithelial, 53
- midgut, 257
 endoscopy, 257–8
- migration, 178
- milk
 cow's, allergy to, 409
 and dairy products, 403
- milk thistle, 539
- minocycline, and PSC, 539
- mitogen-activated protein kinases (MAPK), 382
 inhibitors
 BIRB 796, 382
 CNI-1493, 382
 pathways, 178
- mitogens, 173
- mitomycin, 167
- MK-591, 428
- MLN-02, 425
- models
 adaptive immune
 aberrant T cell development or activation, 35–7, 35
 effector cell function, 33–5, 33
 animal, 7, 25, 93, 176
 see also mice; rats
 CD4⁺, CD45RB^{hi} transfer, 37–8
 CD45RB transfer, 133
 of defective innate immunity, 73
 of DSS-induced colitis, 70
 gnotobiological, 60
 of good practice in decision-making, 313
 immune-mediated inflammatory disease (IMID), 532
 of impaired regulation–41, 37
 in vivo, 25–51
 innate immune
 epithelial, 27–30, 28
 myeloid, 30–3, 32
 murine, 87, 122–6
 rabbit immune complex colitis, 132
 of spontaneous IBD, 41–3, 41
 T cell transfer, 157–8
 Tge26 bone marrow transfer, 40
- modified Truelove and Witts severity index, 328
- molecular markers
 clinical applications of, 514–15
 of future risk, 514–15
- molecular pharming, 366
- molecular profiling, 515
- molecules, adhesion, 133
- monocyte colony stimulating factor (M-CSF), 203
- monocytes, 35, 121, 132–3, 203
- Montreal classification, 4, 213, 214, 236, 464
- Montreal Working Party, 213, 215
- morphogens, 173
- mortality, and CD, 240–1, 240
- motilin, 67
- motility
 changes in CD, 184
 and UC, 184
- mouth, 231–2
- moxibustion, 698
- moxifloxacin, 622
- mucins, 54, 106
 glycosylation of, 37
 MUC2, 30
- Muckle–Wells syndrome, 133
- mucogingivitis, 233
- mucosa
 biopsy misinterpretation of, 247
 extraintestinal consequences of inflammation, 195–211
 flat, 523–4
 intestinal, 52
 and mechanisms of innate immunity, 105–10
- mucosa-associated lymphoid tissue (MALT), 52
- mucosal addressin cell adhesion molecule (MAdCAM-1), 57, 533, 611–3
- mucosal barrier function, 70–1
- mucosal homeostasis, factors affecting, 52–63
- mucosal immunopathogenesis, of HIV/AIDS, 659–60
- mucosal nodularity *see* Crohn's disease, oral (cobblestoning)
- mucosal repair, regulation of, 171, 175–6
- mucosal tags, 233, 255
- mucosal ulcerative colitis (MUC), 444
- mucosectomy, 446, 448, 458
- mucus, 106
- multi-drug resistance, 27–8
- multiple sclerosis, 238, 381, 384–5, 426
 and adalimumab, 684
 and infliximab, 684
 and natalizumab, 685
- multiwell cassettes, 245–6
- muramyl dipeptide (MDP), 17, 71–2, 145
- mutations
 CARD15/NOD2, 234
 and CRC, 222
 IRAK4, 68
 TNFR1A36G, 285
 TNFR2T587G, 285
- myalgias, 195
- mycobacteria, 93, 383
- Mycobacterium*
 avium subsp. *paratuberculosis* (MAP), 393
 tuberculosis, 20, 141, 645–8, 652
- mycophenolate mofetil, 423–4
 and PSC, 538
- mycotic aneurysms, 648
- myelodysplasia, 204
- myeloid cells, 142
- myeloma, 133, 363
- myeloperoxidase, 165
- myelotoxicity, 708
- myocarditis, 238
- myofibroblasts, 88, 140, 170, 178–9
 intestinal subepithelial (ISEMF), 604
 mucosal, 173
 pericryptal, 604
- myopathy, 423
- myosin, 646
 light chain kinase, 106
- NALP3 inflammasome, 132
- naltrexone, and PSC, 541
- nanoparticles, 404
- nasal passageways, 187
- nasopharyngitis, 375
- natalizumab, 238, 385, 425, 478
 in combination with infliximab, 381
 efficacy and safety, 380–1
 mechanism of action of, 381
 medico-legal issues, 708–9
 and microvasculature, 609, 613
 and multiple sclerosis, 685
 in pediatric patients, 590
 pharmacokinetics of, 381
 and PML, 684
 safety issues, 678, 685
 and viral infections, 384
- National Cooperative Crohn's Disease Study, 471
- National Health Service (NHS), 305
 Primary Care Trusts, 306, 309

- Quality and Outcomes Framework (QOF), 309
- Redress Act, 706
- National Institute for Health and Clinical Excellence (NICE), 310–12, 707
- natural history, of CD, 238–41
- natural killer (NK) cells, 27, 88, 98, 126, 532–3
 - and CD1d, 104–5
- nausea, 232, 591
- necrosis, 32, 130, 616
 - avascular, medico-legal issues, 711
 - hemorrhagic, 299
 - piecemeal, 542
- necrotizing enterocolitis, in cancer patients, 299
- necrotizing fasciitis, 627
- negative predicted value (NPV), 280
- negligence, 705
- Neisseria gonorrhoeae*, 292, 296
- nematodes, 184–5
- NEMO, 348–9
- neomycin, 695
- neoplasia, 28, 101, 204, 247, 403, 461
 - colitis-associated, 68, 251–2, 522
 - incidence of, 521
- Neoral, 423, 434
- nephrogenic systemic fibrosis (NSF), 273
- nephrolithiasis, 237
- nephropathy, 205
- nephrotoxicity, 424
- nerves, enteric, 185
- neural networks, 182
- neuritis, optic, 238
- neuro-motor apparatus, in the immune response, 188–9
- neurologic complications, in CD, 238
- neurologic disease, 385
- neuroma, 455
- neuropathy, peripheral, 238, 590
- neutropenia, 199, 625
- neutrophils, 65, 133, 203, 346, 603, 646
 - accumulation of, 165
 - chemotaxis of, 108
 - in pouchitis, 251
 - in UC, 248
- niacin, 410
- nicotine, 188–9, 427
 - and PSC, 536
- nidogen, 175
- night sweats, 195
- nipple valve, 453
- Nippostrongylus brasiliensis*, 138, 183
- nitazoxanide, 632, 635
- nitric oxide (NO), 184–5, 611–12
 - synthase (NOS), 184, 611–12
- nitrofurantoin, 623
- nitroglycerine, 491
- nitroimidazole, 393
 - and postoperative recurrence, 503
- nocardiosis, 384, 684
- nocebo phenomenon, 331
- nodular regenerative hyperplasia (NRH), 544
- non-Hodgkin's lymphoma (NHL), 203, 385, 423, 680–2
- non-peptidyl factors, 171
- non-steroidal anti-inflammatory drugs (NSAIDs), 45, 247, 297–8, 616
 - and arthritis, 558–9
 - and erythema nodosum, 564
 - and IBD relapse, 171
 - and microscopic colitis, 602
 - and pouchitis, 461–3
 - and sporadic CRC, 508–9
 - and UC, 219–20
- norfloxacin, and pregnancy, 573
- Norwegian cohort, 214
- notching, 256
- nuclear receptor superfamily, 338, 347
- nucleotide-binding oligomerization domain 2 (NOD2), 31, 61, 71–2
- nucleotides, 171
- nurse specialist, 706–7
- nutriceuticals, 593
- nutrition, 317
 - and CAC, 509
 - deficiencies in IBD, 409–10
 - enteral, 403
 - in CD, 406, 407–8
 - in evaluation and treatment of IBD, 402–14
 - parameters in pediatric patients, 591
 - parenteral, 592
 - total parenteral (TPN), 198, 483
- nutritional deficiency, 563
 - and cutaneous manifestations, 565
- oat bran, 409
- obesity, 95, 205, 589
 - mesenteric, 237
- obstruction, 230
 - chronic, 3
- occludens, 97
- occludin, 53, 97
- octreotide, 411
- ocular disease, 559–60
 - epidemiology of, 559
 - pathogenesis of, 559
 - treatment of, 559–60
- odynophagia, 232
- Ogilvie's syndrome, 445
- oligodeoxynucleotides (ODNs), 70, 425
- oligofructose, 406
- oligomannosidic epitope, 280
- oligonucleotides, 86–7
 - antisense, 369
 - mechanism of action of, 369, 370
 - pharmacokinetics of, 369
 - production of, 369
 - phosphorothioate, 369
- oligospermia, 569, 577
- olsalazine, 417, 420, 430
 - and CD, 474
 - and hospitalization, 433
- oral, 431
 - and pregnancy, 572
 - toxicity of, 420, 432
- omega-3 fatty acids, 593
- omega-6 fatty acids, 592–3
- omentum, 456
 - greater, 446
- oncogenes, 540
 - c-src*, 512
 - k-ras*, 511–12, 514–15
- ondansetron, and PSC, 541
- onercept, 373, 373, 375
- Ontario Medical Association, Guideline Advisory Committee (GAC), 312
- OPC-6535, 426
- opioids, 558
- opsonization, 197
- oral cavity, 255
- oral clefts, 573–4
- oral disease, 233
- oral tolerance, 58–9, 100, 102
 - general mechanisms of, 59–60
- orchitis, 36
- Organization for Teratology Information Specialists (OTIS), 577
- organum vasculosum laminae terminalis (OVLT), 196
- ornidazole, 393
 - and postoperative recurrence, 503
- orthotopic liver transplantation (OLT), 258–9, 540–1, 540
- osteoblasts, 142
- osteoclastogenesis, 665
- osteomalacia, 672
- osteomyelitis, 627, 648
- osteonecrosis, 423, 671, 711
- osteopathy, 700
- osteopenia, 312, 471, 594, 666
- osteoporosis, 42, 342, 423, 445, 665–6, 699
 - and corticosteroids, 665–6, 669–70
 - medico-legal issues, 711
 - in pediatric patients, 594
 - and PSC, 538, 541
 - treatment in IBD patients, 669–703
- osteoprotegerin (OPG), 665–6
- ostomy, 454, 609, 616
- outcome measures, 309
 - type of, 330
- outcomes, 217, 323–36
- oxalate, 411
- oxazolone, 32–3, 105, 136
- oxidative burst, 346
- p53, 514
- pain
 - abdominal, 196, 215, 233
 - in CD, 229, 231
 - anal, 296
 - back, 554–5, 557
 - epigastric, 232
 - perineal, 454–5
 - tolerance of, 185–6
- pamidronate, 90
- pancolitis, 29, 39, 260, 268, 284, 417, 455, 490
 - and risk of CRC, 519
- pancreas
 - autoimmune pancreatitis (AIP), 538
 - and CD, 238
- pancreatitis, 238, 256
- pancytopenia, 198, 685
- Paneth cells, 30–1, 54, 71, 97
 - and defensins, 107
 - disruption of, 106
 - metaplasia, 604
 - and TLR9, 70

734 Index

- panning, 363
Papanicolaou smears, 569
PAR-101, 632
paracetamol, 220
and arthritis, 558
paracoccidiomycosis, 297
paralysis, facial, 233
parasites, 296
stool, 651
particles, in diet, 404
pathogen-associated molecular patterns (PAMPs), 60–1, 65–6, 533
pathogens
definition of, 96
enteric, 295
food-borne, 644
intracellular, 33
pathology, practical, in IBD, 245–53
patient care, 2
patient management, in IBD, 245–53
patient record systems, computer-based (CBPRSs), 317
patient-defined remission, 328
patients
antibody expression in, 6
asymptomatic *C. difficile* carrier state of, 627
communicating risk to, 685–8
legal pitfall in treatment of, 705–12
nourishment status of, 483
oncology, 625
preparation for surgery, 483–4
pretreatment evaluation in UC, 415, 417
profiling of, 4
risks vs. benefits for IBD therapy, 678–92
pattern-recognition receptors (PRRs), 17, 19, 31, 65–6, 96–7
pediatric population, IBD in, 584–600
pediatric ulcerative colitis activity index *see* colitis, ulcerative, pediatric activity index
pediatrics
CDAI in, 326
of IBD, 10, 12–13
and surrogate decision making, 686
PEGylation, 368
pelvic dead space, 454
pelvic pouch, salvage surgery for, 452
pelvic sepsis, 250
pelvis, packing of, 447
penicillamine, 298
penicillin, 433, 622, 625
Pentasa, 417, 419–20, 473, 501–2
peptic ulcer disease, 1
peptide growth factors, 171
peptides, 54, 171
antimicrobial, 70–1
RDP58, 426
regulatory, 182
trefoil, 171, 174
peptidoglycan-polysaccharides, 96
peptidoglycans, 66, 107
percutaneous transhepatic cholangiography, 534
perforin, 58, 183
perfusion, defective, 167
perianal disease, 21, 230–1, 233, 490
activity index (PDAI), 327
in CD, 491–4
classification of, 232, 491
US assessment of, 268
perianastomotic disease, 486
perilymphangitis, 662
perineum, 590
periodic acid–Schiff (PAS) stain, 246
peritoneal irritation, 3
peritonitis, 144, 236, 299, 445, 500, 615, 649
peroxidases, 107
peroxides, 107
peroxisome proliferator-activated receptors (PPARs), 338
alpha (PPAR α), 347
delta (PPAR δ), 347
gamma (PPAR γ), 347–8, 428
anti-inflammatory properties of, 347
expressions and functions of, 347
ligands of, 347
treatment of colitis with agonists, 347–8
personalized medicine, 714
Peyer’s patches, 36, 43, 97–8, 104, 144
and induction of inflammation, 158–9
lymphocyte response in, 55–6
phage display libraries, 363
phagocytosis, 96, 197
epithelial, 54
pharmabiotics, 396
pharmacy benefit management (PBM), 303–5
pharynx, 232
phlegmon, 482
phosphatase, 258
phospholipases, 178
physical examination, 650
physiological systems, modulation of
inflammation by, 186–9
pirfenidone, and PSC, 539
piroxicam, 45
Pistacia lentiscus, 697
placebo, vs. active comparator, 324
placebo response, 330–1, 700
Plantago ovata, 409
plantain (banana), 406
plasmacytosis, basal, 246, 294
plasmids, 368
plasminogen-activating inhibitor (PAI), 164
platelet aggregation, 201
platelet counts, 293
platelet-derived growth factor (PDGF), 172
platelet–leukocyte aggregates (PLAs), 164
Plesiomonas, 294–6, 649
shigelloides, 296
pleuropericarditis, 238
pneumaturia, 235
Pneumocystis carinii, 424, 434
pneumonia (PCP), 684
jiroveci, 659
pneumonia, 384, 424, 434, 659, 684
pneumoperitoneum, 445
pneumothorax, 700
polyamines, 69, 171
polyangiitis, 532
polyarteritis nodosa, 299
polyethylene glycol, 269, 363, 368
polymer sealants, 256
polymerase chain reaction (PCR), for *C. difficile* toxins, 631
polymers, toxin-binding, 636
polymorphisms, 74–5
Arg702Trp, 17
Asp299Gly, 68, 74
Gly908Arg, 17
Leu1007insC, 17
and pouchitis, 461
Thr399Ile, 68, 74
polypectomy, 263, 652
polypeptides, spasmolytic, 174
polyposis, adenomatous, 69
polyps
adenomatous, 509
biopsies of, 247
colonic, 652
inflammatory, 463, 524
populations, reagent grade, 714
Porphyromonas gingivalis, 109
positional cloning, 16
positive predicted value (PPV), 280
positron emission tomography (PET), 273–4, 540, 587
post-capillary venule (PCV), 98
postoperative recurrence *see* recurrence, postoperative
potassium chloride, 298
pouch, ileal *see* ileal pouch
pouch, ileal *see* ileal pouch, pelvic *see* pelvic pouch
pouchitis, 4–5, 70, 219, 246, 250–1, 461–3, 615
antibiotics in, 394–6, 462
clinical trials, 396
appearance of, 250–1
categorization of, 462
chronic, 284
and ciprofloxacin, 462
classification of, 463
clinical characteristics and management, 461–8
diagnosis of, 248, 462
disease activity index (PDAI), 395, 398, 462
genetic variants in, 5
idiopathic, 462
and metronidazole, 462
natural history of, 462
NSAID-induced, 464
and pregnancy, 573
presentations of, 461–2
probiotics in, 397–8
clinical trials, 398
and PSC, 537
refractory, 281, 626
secondary, 462
treatment of, 463
Powell–Tuck index, 328
prebiotics, 406, 409, 698–9
for *C. difficile*, 636
PRECISE trials, 375, 475
prednisolone, 177, 338, 378, 420, 422, 472, 695, 697–698, 708
and arthritis, 559
and CD, 471
and colonic disease, 472
enemas, 588

- metasulfobenzoate, 420
- and osteoporosis, 670
- and pregnancy, 574
- and PSC, 539
- prednisone, 141, 204, 327, 420–1, 428–9, 661, 682, 684
- and CD, 471, 665
- oral, 431
- in pediatric patients, 588
- and pregnancy, 574
- and pyoderma gangrenosum, 565
- toxicity, 432
- pregnancy
 - effect on IBD, 570–1
 - in IBD, 568–83
 - medications during, 572–7
 - see also under individual drug names
 - and methotrexate, 472
 - outcomes, 570
 - and UC, 219, 458
- prescriptions, 304–5
- presentations, in pediatric IBD, 584–5
- pretreatment, patient evaluation in UC, 415, 417
- preventive medicine, 313
- prevotella, 623
- primary sclerosing cholangitis (PSC), 258–9
 - 519–520, 530–42
 - and antibiotics, 539
 - antifibrotic therapy for, 539
 - association with UC, 535–6
 - biliary and colorectal cancer in, 536–7
 - clinical features of, 534
 - corticosteroid therapy for, 538
 - endoscopic treatment for, 539
 - epidemiology of
 - etiology of, 530–4
 - genetic susceptibility to, 530–2
 - immune mediation of, 532–4
 - and immunosuppressants, 538–9
 - laboratory investigations of, 534
 - natural history of, 535
 - onset of, 536
 - and orthotopic liver transplantation, 540–1
 - outcome of, 536
 - pathological features of, 534–5
 - possible causes of, 530
 - and pouchitis, 537
 - prevalence in UC, 529
 - prognostic models of, 535, 536
 - radiographic features of, 534
 - relationship with IBD, 535–7
 - small duct (SD-PSC), 542
 - and smoking, 536
 - staging of, 534–5, 535
 - symptomatic treatment for, 541
 - treatment of, 537–9
 - and UC/CRC, 222, 519, 522, 536–7
 - UDCA therapy for, 537–9
- principal component analysis (PCA), 288
- probiotics, 392–401
 - for *C. difficile*, 636
 - and postoperative recurrence, 503–4
 - and pouchitis, 462–3
- proctectomy
 - completion, 444
 - nerve-sparing, 447
 - and perianal disease, 493
 - posterior plane of dissection, 447
- proctitis, 221, 231, 292–5, 417, 429–32
 - diversion, 249
 - herbal remedies in, 697
 - infectious, 292
 - symptoms of, 293
 - treatment for, 655
 - infective, 649, 650
 - ulcerative (UP), 87, 296, 418
 - and UC, 212–27
- proctocolectomy, 218, 222, 250, 490
- prophylactic, 521
 - restorative, 445–52
 - thrombocytosis, 461
 - total (TPC), 445, 454–5, 461
- proctosigmoiditis, 214–15, 220, 417
 - young-onset, 218
- prognosis, of CD, 238–41
- Prograf, 423
- program of all-inclusive care for the elderly (PACE), 306
- progressive multifocal leukoencephalopathy (PML), 381, 384, 425, 478, 613, 684–5
- prolapse, rectal, 29, 35, 39, 648–9
- proliferation-inducing ligand (APRIL), 55–6, 71
- prophylaxis, 498
 - medical, 505
- prospective randomized controlled trials (PRCTs), 308
- prostacyclin, 166
- prostaglandin receptor, 20
- prostaglandins, 166, 171, 182, 196
 - COX2-dependent E₂ (PGD₂), 108
 - COX2-dependent E₂ (PGE₂), 56, 108
 - E₂, 605
 - F₂α, 108
- prostanoids, 108, 184, 611
- prostate, 134
- protease inhibition, 429
- protease-activated receptors (PARs), 165
- proteases, 183
 - granzyme, 58
- proteasomes, 86
- protein kinases, 178
- proteins
 - acute phase, 197
 - amebapore, 646
 - Apaf1, 349
 - B7 family, 54
 - C, 164–5, 201–2
 - C-reactive, 285
 - CD1 family of, 104
 - contractile, 647
 - CREB binding (CBP), 342
 - CRP, 197
 - in diet, 404
 - DLG5, 18
 - ECM1, 21
 - epithelial X-box binding, 30
 - fusion, 426
 - G see G proteins
 - GM-CSF, 142
 - GMEBs, 343
 - gp130, 134
 - IB, 341
 - IL-18bp.Fc, 126
 - IRGM, 20
 - MAGUK family, 18
 - MyD88, 349
 - NOD1, 349
 - NOD2, 17, 31, 349
 - non-mAb TNF-neutralizing, 375
 - OCTNs, 19
 - recombinant see recombinant proteins
 - rho, 620–1, 647
 - RICK, 349
 - S, 164, 201–2
 - SAA, 197
 - Smads, 85–7
 - surface effector, 647
 - TL1A, 5, 7, 20
 - trefoil, 29
 - ZO-1, 70
- proteinuria, 205
 - nephrotic-range, 237
- Proteobacteria, 95
- proto-oncogenes, activation of, 512
- protozoans, 393
- pruritus, 539
 - and PSC, 258, 541
- pseudoephedrine, 297
- pseudogout, 557
- pseudomembranes, 295, 652
- Pseudomonas*, 104, 107
 - fluorescens*, 5–6, 72, 280, 462
- pseudopolyps, 260
- pseudosacculation, 235
- psoriasis, 36, 140–1, 544, 681, 685
- psychiatric complications, in CD, 238
- psychosis, 423
 - corticosteroid-induced, 595
- psychosocial functioning, in pediatric IBD, 594–5
- puberty, delay of, 591
- pulmonary embolus, 237
- purine, 203
 - analogs and postoperative recurrence, 502–3
 - immunomodulators and IBD, 509
- Purinethol, 423
- putrescine, 171
- pyloroplasty, 489
 - Heineke–Mikulicz, 487
- pyoderma gangrenosum, 230, 564–5
 - therapies for, 564
 - variants of, 564
- pyostomatitis vegetans, 233, 255, 563
- pyrazinamide, 653
- pyridoxine, 202
- pyrogen, endogenous, 132
- quality of life, 457, 679
 - and CD, 240, 469
 - in pediatric patients, 595
 - score, 313
- quality-adjusted life-year (QALY), 309–11, 317, 686
- quinolones, 295, 653
 - and pregnancy, 573

736 Index

- rabbits, immune complex colitis model, 132
- Rachmilewitz index, 328
- radiation, exposure to, 270–1
- radiography
 - abdominal, 652
 - barium, 257
 - and CD, 237
- radiology, 254, 279–91
- radiotherapy, and pouch failure, 448
- Radix sophorae flavescens*, 695
- ramoplanin, 632
- randomization, 323–4, 324
- randomized controlled trials (RCTs), 310, 333, 682, 694–5
- ranitidine, 602
- rats
 - arthritis models in, 666
 - athymic (nude), 36
 - and colon cancer, 509
 - HLA-B27/β2M, 36
 - TNBS-induced colitis in, 141, 144
- RDP58, 426
- reagent grade populations, 4
- receptors
 - for activated factor of nuclear factor kappa B (RANK), 665
 - caspase recruitment domain (CARD), 61, 65
 - chemokine *see* chemokine receptors
 - glucocorticoid *see* glucocorticoid receptors (GR)
 - IL-7R, 34
 - nucleotide-binding oligomerization domain (NOD), 61, 65
 - expression in health and disease, 71–2
 - general role of, 70–1
 - pattern-recognition *see* pattern-recognition receptors (PRRs)
 - peroxisome proliferator-activated *see* peroxisome proliferator-activated receptors (PPARs)
- retinoid X (RXR), 347
- toll-like *see* toll-like receptors (TLRs)
- recombinant proteins, 367–9
 - mechanisms of action of, 367–8
 - pharmacokinetics of, 368–9
 - production of, 367–8
- rectal bleeding, 231
- rectal cuff, 463–4
- rectal foam, 587
- rectosigmoid, 294
 - inflammation of, 269
 - junction, 218
- rectum, 34, 185, 213, 218, 222, 231, 250, 259, 268, 292
 - conserved, 596
 - fistulas of, 235
 - sparing of, 260, 490
 - US assessment of, 268
- recurrence
 - postoperative
 - assessment of, 499
 - in CD, 498–507
 - location and disease phenotype, 499–500
 - risk stratification of, 500
 - and smoking, 500
 - treatment algorithm for, 505
- reflux esophagitis, 255
- rehydration, 653
- Reiter's syndrome, 648, 650
- relapse
 - on azathioprine, 476
 - biologic underpinnings of, 170–81
 - in CD, 239
 - early, 475
 - epidemiology in CD, 470–1
 - treatment of, 475
- relative diagnostic odds ratio (RDOR), 282
- Remicade, 678
 - see also* infliximab
- remission
 - biologic underpinnings of, 170–81
 - definition of, 331–2
 - management of, 473–8
- renal failure, 205
- renin-angiotensin system, 611
- repair
 - perturbation of, 178–9
 - stimulation of, 176–9
- repifermin, 173, 176, 426
- reporting systems, spontaneous, 333
- research, genetic, 713
- resection, 571
 - in CD, 239
 - bowel, 485–6
 - esophageal, 255–6
 - margins, 486
 - upper tract, 232
- reserpine, 189
- resins, anion-binding, 635
- resiquimod (R-848), 70
- resistin, 205
- resolvins, 108–9
- response, definition of, 331–2
- restenosis, 166
- restitution, 170, 174
- retinoic acid, 57, 89, 140, 144
- retroperitoneum, 236
- reviparin, 427
- ribonucleic acid (RNA)
 - double-stranded (dsRNA), 70
 - messenger (mRNA), 369
- ridogrel, 428
- rifalazil, 632
- rifamixin, 393, 395
- rifampicin, 383, 632, 635, 653
 - and PSC, 541
- rifaximin, 428, 632–3, 635
 - and IPS, 465
 - and pouchitis, 462–3
 - and pregnancy, 573
- Riley index, 330
- risedronate, 671–2
 - and pregnancy, 574
- risk
 - assessment, 679–85
 - communication of, 686–8
 - of the disease, 679–80
 - factors for CRC, 262
 - medico-legal, 705–12
 - patient perception of, 685–6
 - in perspective, 685
- score for PSC, 535
 - vs. benefits of IBD therapy, 678–92
- rolling, 379, 611
- Rome classification, 4
- ropivacaine, 428
- rosiglitazone, 347–8, 428
- Rotavirus, 102, 107
- Roux Y duodenostomy, 489
- Rowasa, 417
- Rutgeerts endoscopic grading scale, 261–2, 262, 328
- S-pouch, 449
 - creation of reservoir, 450
- Saccharomyces*, 280
 - boulardi*, 429, 636
 - cerevisiae*, 5–6, 72, 236, 279–80, 462, 586
- sacroiliitis, 554–5, 557
- safety
 - in clinical trials, 332–4
 - data provenance, 678–9
 - issues, 678
- St John's wort, 700
- St Marks Hospital score, 251, 328
- salazopyrine, and microscopic colitis, 606
- salivary glands, 171
- Salmonella*, 69, 71, 102, 107, 292, 294–5, 445, 556, 643–5, 647–999
 - dublin*, 108, 648
 - enteritidis*, 645
 - gastroenteritis*, 296
 - typhimurium*, 20, 106, 108, 144, 655
- salmonellosis, 648
- Salofalk, 417, 419, 473, 501
 - Granu-Stix, 417, 419
- sample sizes, 324–5
- Sandimmune, 423, 434
- saporin, 121
- sarcoidosis, 299, 564
- sargramostim, 142, 176
- satiety, 232
- scatter factor, 173
- Schilling test, 410
- Schistosoma*, 646–7, 649, 651–2
 - hematobium*, 647, 649
 - japonicum*, 647, 649
 - mansoni*, 89, 185, 647, 649, 652
- schistosomiasis, 645, 649, 651–2
- scintigraphy, 268, 273, 587
- scleritis, 559–60
- secretory component (SC), 187
- SEER database, 682
- segmental, chronic colitis associated with
 - diverticular disease (SCAD) *see* colitis, diverticular
- selectins, 57, 61, 379
 - E-selectin, 379, 611–12
 - L-selectin, 159, 379, 611–12
 - P-selectin, 611
- selection bias, 323, 333
- selective serotonin reuptake inhibitors (SSRIs), 602
- selenium, 405, 409
- semen
 - abnormalities in, 577

- damage to, 578
- quality of, 569, 578
- sensory nerves, and inflammation, 185–6
- Seo index, 328
- sepsis, 281, 297, 455, 490, 492, 680–2
 - perianal, 596
 - perineal, 590
 - staphylococcal, 384
- septic shock, 130, 455
 - LPS-induced, 67
- septicemia, 299, 627, 648
 - Yersinia*, 653
- serine kinases, 85
- serines, 339
- serological markers, 4, 279–80
- serologics, 279–91
 - profiles of CD, 236–7
- serology, 651
- serotonin, 67, 183, 186
- sertraline, 602
- serum C-reactive protein, 267
- serum orosmumucoid, 587
- setons, 492, 590
- severe combined immune deficiency (SCID), 138, 140, 186
- sexual dysfunction, 569
- sexual function
 - and fertility, 568–70
 - in men, 569–70
 - in women, 568–9
- shared decision making *see* decision support (shared decision making)
- shiga toxins, 295, 646–8
- Shigella*, 292, 294–5, 645, 647–8, 652–3
 - dysenteriae*, 108
- shigellosis, 247, 294–5, 644, 648, 653
- shock, 299
- short bowel, 198
- syndrome, 173, 176, 410–11, 483
- short stature, assessment of, 592
- short-chain fatty acids (SCFAs), 96, 171, 410, 427, 463, 614
- sibling pair method, 17
- sigmoid colon, 248
- sigmoidoscopy, 215
 - cost-effectiveness of, 317
 - flexible, 263, 522
 - rigid, 650, 652
- signal transducer and activator of transcription
 - 1 (STAT1), 86, 126
 - 3 (STAT3), 30–1, 133
 - 4 (STAT4), 121
- signal transduction inhibitors, 382
- signaling pathways, NF- κ B, 29–30, 61, 86
- signalosome, COP9, 86
- silymarin, and PSC, 539
- simian immunodeficiency virus (SIV), 659
- simple clinical colitis activity index, 328
- single immunoglobulin IL-1 receptor-related molecule (SIGIRR), 69
- Sjögren syndrome, 203
- skin
 - disease and IBD, 562–7
 - focal lesions of, 34
- skip areas, 260
- Smads
 - signaling by, 85–6
 - Smad2, 41, 85–6
 - Smad3, 41, 85–6
 - Smad4, 85
 - Smad7, 86–7
 - biological activity of, 87
- small bowel bacterial overgrowth, 465
- small bowel disease, 21
 - extensive, 472–3
- small bowel follow-through (SBFT), 257, 266, 268–9, 272, 281, 585
- smoking, 217, 221
 - and CD, 470–1, 474
 - of pouch, 464
 - and postoperative recurrence, 500
 - and pouchitis, 461
 - and PSC, 536
 - and UC, 219
- smooth muscle cells, 140, 170, 178
- smooth muscle contraction, and inflammation, 184–5
- social health maintenance organization (Social HMO), 306
- Society of Healthcare Epidemiologists of America (SHEA), 637
- Society of Internal Medicine, 308
- sodium, 410–11
 - 2-bromooctanoate, 19
 - cromoglycate, 565
 - hydrogen sulfide, 403
 - hypochlorite, 637
- salicylate, 346
- soft drinks, 403
- solitary rectal ulcer syndrom (SRUS), 298
- somatomedins, 173–4
- somatostatin, 67
- SONIC trial, 477
- sorbitol, 269
- Spanish Society of Rheumatology, 683
- SPD476, 420
- spermidine, 171
- spermine, 171
- sphincterotomy, 491
- Spirochaetes, 95
- spleen, 33, 347, 649
- splenectomy, 200
- splenic flexure, 213, 218
- splenomegaly, 31, 39
- spondylitis, 230
- spondyloarthropathies, 36, 273, 554
- sporotrichosis, 384, 684
- stabilizers, in diet, 404–5
- Staphylococcus*, 95
 - aureus*, 621, 627
 - methicillin-resistant (MRSA), 445
 - epidermidis*, 94
- star sign, 272
- steatorrhea, 233, 672
- steatosis, 542–3, 542, 681
 - hepatic, 258, 699
- stem cell factor (SCF), 108
- stem cell transplantation, 21, 478
- stem cells, gastrointestinal, 176
- stenosis, 230, 235, 256, 571
 - anal, 491
 - intestinal, 171
- stenting, 257, 259
- steroids, 214, 216, 218, 255–6, 376, 614
 - adverse reactions to, 707–8
 - and arthritis, 558
 - in CD, 470
 - dependence on, 347
 - and fertility, 569
 - and IBD, 509
 - and ileocecal disease, 474
 - and ocular inflammation, 560
 - in pediatric patients, 592
- side effects of, 588
- Still's disease, 376
- stoma
 - creation of, 456
 - and pregnancy, 569
 - preoperative marking of, 484
- stomach, 174, 231, 256
 - microbiota of, 94
- stomatitis, aphthous, 233, 562–3
- stool cultures, 294
- stool tests, for *C. difficile*, 630
- straight ileal anastomosis (SIAA), 596
- streptococci, 544
 - α -hemolytic, 94
- Streptococcus*
 - milleri*, 544
 - mutans*, 107
 - salivarius* *subsp. thermophilus*, 429, 463
- streptomycin, 654
- stress, 101
 - role in IBD, 189
- strictureplasty, 486–9, 498
 - Finney, 486–9, 488
 - Heineke–Mickulitz, 486–7, 487, 489
 - isoperistaltic, 489
- strictures, 21, 171, 174, 182, 229, 234, 446, 652
 - bowel, 483
 - capsule retention by, 257–8
 - in CD, 235
 - esophageal, 232
 - intestinal, 274
- stromal cells, 142
- stromolysin (MMP-3), 175
- Strongyloides*, 296, 586
- strongyloidiasis, 295, 651
- study design, 323–36
- subepithelial dome (SED), 55
- substance P, 184, 611
- sucrose, and refined sugar, 402–3
- sulfanilamide, 417
- sulfapyridine, 417–19
- sulfasalazine, 199–200, 202, 237, 346, 410, 417–19, 421, 423, 427, 661, 695, 697
 - adverse reactions to, 707
 - and arthritis, 558–9
 - and CD, 473
 - and colonic disease, 472
 - and conception, 577
 - and fertility, 569
 - and hepatitis, 544
 - and hospitalization, 433

738 Index

- sulfasalazine (*Cont.*)
 - oral, 429, 431–2
 - in pediatric patients, 587–8
 - and postoperative recurrence, 501–2
 - and pregnancy, 572
 - side effects of, 418–19, 430–2, 472
- sulfide, fecal, 403, 409
- sulfmethoxazole, 434
- sulfonamides, 572, 622
- sumoylation, 339
- superiority trials, 325
- superoxide, 167
- suppositories, 422, 429, 587
 - mesalamine, 429, 431
 - opium, 465
- surface molecule, CD45RB, 37–8
- surgery
 - in acute colitis, 710
 - for CD, 239, 481–97
 - bowel resection, 485–6
 - emergency, 482
 - small bowel, 485–9
 - for CRC, 521
 - emergency, 455–6, 482
 - and fertility, 569
 - for gastroduodenal disease, 489–90
 - hand-assisted laparoscopic (HALS), 445, 450
 - impact of medical therapies on, 485
 - indications for, 445
 - large bowel, 490–1
 - medico-legal issues, 711
 - minimal invasive, 450–1
 - open approach, 446
 - in pediatric patients, 595–6, 596
- salvage, 452
 - for UC, 444–60
 - institute results, 456–8
- surveillance
 - efficacy and cost-effectiveness of, 524
 - endoscopic, 522–5
- susceptibility genes, identification in IBD, 17–19
- susceptibility loci
 - ARCP2, 21
 - ATG16L1, 17
 - ECM1, 21
 - IL2, 21
 - IL10, 17, 21
 - IL21, 21
 - IL23R, 17
 - IRGM, 17
 - NELL1, 17
 - PTGER4, 17
- Sutherland index, 329
- Sweet's syndrome, 565
- sympathectomy, chemical, 188
- syphilis, 295–6
- systemic lupus erythematosus, 105, 205, 299, 429
- systemic sclerosis, 105
- T cell receptors (TCR), 35–6, 54–5, 102, 105, 605
- T cells, 29, 31–2, 130
 - CD1, 187
 - CD1d, and NK cells, 104–5
 - CD3, 28, 30, 32, 55
 - inhibition of, 379
 - CD4, 26–7, 32–3, 40, 54, 57–9, 88, 99
 - accumulation in IBD tissue, 84
 - diversity of, 26
 - and HIV infection, 659–61
 - inhibition of, 379
 - interaction with IECs, 102–3
 - and TLR expression, 73
 - CD8, 27, 38, 40, 54, 99
 - interaction with IECs, 104
 - CD25–58, 99
 - CD28, 32, 40, 54, 56–8
 - CD31, 611
 - CD40, 31, 34–5, 54
 - inhibition of, 378–9
 - CD40 ligand (CD40L), 31, 34–5
 - CD40L, inhibition of, 378–9
 - CD42, 647
 - CD55, 54
 - CD80, 56, 102
 - CD86, 56, 102
 - CD105, 187
 - CD154, 32
 - effector, 26, 72, 160
 - and adaptive immune models, 33–5
 - GALT-associated, 98
 - inhibitors of activation, 378–9
 - and innate immunity, 66
 - of lamina propria, 57–8
 - LFA knockout, 160
 - naive, 98
 - natural killer *see* natural killer (NK) cells
 - phenotype of, 98–9
 - presentation of antigens to, 186–7
 - regulatory (Tregs), 27, 36, 38, 55, 57, 65, 89
 - adaptive or induced (aTregs), 37, 133
 - inducible (iTregs), 133
 - natural (nTregs), 37, 131
 - role in gut mucosal immunity, 58–9
 - trafficking, 158
- T helper cells, 55
 - Th1, 7, 27, 29, 32–3, 37–9, 42, 55–6, 72, 121–4
 - cell responses in CD, 87–9
 - Th2, 27, 33, 55–6, 72
 - Th3, 55–6, 59, 139
 - Th17, 7, 27, 32–3, 38, 42, 72
 - and IL-6, 133
 - link between TGFβ and IL-21, 89
- tacrolimus, 216, 423–4, 434
 - in pediatric patients, 590, 596
 - and pregnancy, 575
 - and PSC, 539, 541
 - and pyoderma gangrenosum, 565
 - and pyostomatitis vegetans, 563
- tagged white cell scanning, 273
- tamarins, 380
 - cotton-top, 41
 - and CRC, 508
- technetium-99m-HMPAO, 273
- teicoplanin, 632–3
- telomeres, shortening of, 511
- tenascin, 604–5
- tenesmus, 299, 648–9
- tenofovir disoproxil fumarate, 659
- testosterone, 666
 - transdermal, 541
- tetomilast, 426
- tetracyclines, 296, 622
 - and IPS, 465
 - and pouchitis, 462
- Texas Medication Algorithm Project, 312–13
- thalassemia, 648
- thalidomide, 163, 238, 565
 - and HIV infection, 660
 - and microvasculature, 613
 - and pregnancy, 575
- therapeutics
 - common dilemmas in CD, 475–8
 - cytokine-directed strategies, 131
 - manipulation of microbiota in IBD, 392–401
 - and microscopic colitis, 606
 - non-targeted, 337–59
 - for pediatric IBD patients, 587–90
 - and postoperative recurrence in CD, 498–507
 - site-specific
 - adverse effects of, 382–5
 - classes of, 362–9
 - costs of, 385–6
 - current and emerging, 369–82
 - limitations of, 382–6
 - and treatment of CD, 469–80
 - and treatment of UC, 415–43
- therapy
 - anti-TNF, 472–3, 475–7
 - antifibrotic, 539
 - antiretroviral (ART), 659–61
 - biologic, 477, 505
 - cessation of, 478
 - and infections, 478
 - loss of response to, 477–8
 - medico-legal issues, 708–9
 - in pediatric patients, 590
 - and pregnancy, 575–7
 - risks vs. benefits of
 - bisphosphonate, 594
 - corticosteroid, 538
 - and cutaneous manifestations of IBD, 565–6
 - episodic vs. scheduled, 477
 - failure of, 483
 - general supportive, 653
 - heparin, 710
 - immunoglobulin, 636
 - immunosuppressive, 203, 284
 - impact on surgery, 485
 - INH, 684
 - predictor of response to, 284
 - probiotic, 429
 - prophylactic, 498
 - protease inhibitor-based, 659
 - rescue, 434
 - site-specific for IBD, 361
 - targeting microvasculature for, 613
 - UDCA, 258, 520, 533, 536–9
- thiazoles, 426
- thiazolidinediones (TZDs), 347–8
- 6-thioguanine nucleotides (6-TG), 204, 544, 575, 589
- thiopurine methyltransferase (TPMT), 199, 589, 708

- thiopurines, 472, 474, 476–7, 590
 and lymphoma, 476
 medico-legal issues, 708
- threonine kinases, 85
- thrombin, 164–5, 201
- thrombin–antithrombin (TAT) complexes, 164–5
- thrombocytopenia, 199, 202
- thrombocytosis, 164, 201, 462, 586–7
- thromboembolic prophylaxis, 483
- thromboembolism, 164, 202, 379
 systemic, 157
- thrombolympangitis, 662
- thrombomodulin, 165
- thrombophilia, 202
- thrombopoietin, 201
- thrombosis, 202, 237
 arterial, 200
 cerebral venous, 200
 cerebrovascular, 238
 deep venous, 200
 evaluation in IBD, 201
 hepatic vein (Budd–Chiari), 200, 544
 and IBD, 164–6
 portal vein, 200
 venous, 237
- thrombotic thrombocytopenic purpura, 648
- thromboxane, 157, 166, 611–13
 in inflammation, 166–7
- thumbprinting, 626
- thunder god vine, 695
- thymic stromal lymphopoietin (TSLP), 56, 71, 99
- thymocytes, 37–8, 105
 cortical, 104
- thymogenesis, 29
- thymus–35, 37, 40, 98, 187
- tight junctions, 97–8
 disruption of, 106
 leaky, 103
- tincture of opium, 433
- tinidazole, 632
 and pouchitis, 463
- tinzaparin, 427
- tissue culture cytotoxicity assay, 630–31
- tissue factor, 165
 pathway inhibitor (TFPI) system, 164
- tissue plasminogen activator (tPA), 164
- tissue-specific inhibitors of metalloproteases (TIMPs), 88, 175
- titanium oxide, 404
- tixicortol, 420
- tobramycin, 394, 427–28
- tocilizumab, 376
- tolerogens, 32
- tolevamer, 636–7
- Toll-interacting protein (Tollip), 61, 67
- toll-like receptors (TLRs), 19, 27, 61, 65–6, 109–10, 188
 expression
 in health and disease, 66–70
 profiles of, 67
 general role of, 70–1
- TLR1, 66
- TLR2, 61, 66
 signaling in intestine, 69
- TLR3, 61
 and dsRNA, 70
- TLR4, 30, 54, 61, 66–9, 109–10, 349
 and cancer susceptibility, 68, 509
- TLR5, 61, 349
 role as flagellin receptor, 69
- TLR6, 66
- TLR7, 61, 69–9
- TLR8, 69–70
- TLR9, 61, 349
 and bacterial DNA, 70
- tormentil, 697
- total parenteral nutrition (TPN), 198, 483
- toxic colon, 295
- toxic megacolon, 184, 230, 261, 295, 433, 445, 455–6, 482
- toxins
 bacterial, 602
 CDT A & B, 621
 cholera, 108, 646
 disruption of export, 106
 in herbal remedies, 700
 shiga, 295, 646–8
- Toxoplasma gondii*, 20, 69, 107, 141
- traditional Chinese medicines (TCMs) *see* Chinese medicine
- transactivation, 341
 factors determining, 343
 NF- κ B-mediated, 348–51
- transcription coactivators, p300, 86–7
- transcription factors
 AP-1, 342
 FOXp3, 37, 58–9, 139
 GATA3, 33, 126
 nuclear factor kappa B (NF- κ B), 32, 342, 348–51, 348, 350–1
 ROR[1]t, 33
 STAT-4, 33–4
 T-bet, 393
 XBPI, 30
- transcytosis, 97
- transferrin saturation, 199
- transforming growth factor (TGF)
 TGF α , 172
 TGF β , 32–3, 55, 59–60, 82, 119, 139–40, 172, 183
 and nutrition, 405, 592
 regulation of gut inflammation by, 84–7
 signaling pathway, 85
 and Th17 cells, 89
- TGF β 1, 40–1, 85
- transporters, ATP-binding, 27–8
- transrepression, 341–3, 341–2
 factors determining, 343
 via DNA binding, 341–2
 without DNA binding, 342–3
- trapidil, 166
- TREAT registry, 385, 679, 681, 708
- treatment
 algorithm for UC, 431
 goals in UC, 417–29
 of IBD in HIV patients, 662
 legal pitfalls in, 705–12
 maintenance, 374
 of microscopic colitis, 605–6
- trefoil factor family (TFF), 174
- trefoil peptides *see* peptides, trefoil
- Trendelenberg positions, 451
- Treponema pallidum*, 292
- triacyl lipopeptides, 66
- trials *see* clinical trials
- triamcinolone, 338
 acetone, 565
- triazolopyrimidine, 166
- tricellulin, 97
- Trichinella spiralis*, 183
- trichiuriasis, 645
- Trichuris*, 138, 349
muris, 138, 141
suis, 429
trichiura, 646–7, 649, 652
- trichuris dysentery syndrome, 647, 649
- TRIF signaling pathway, 70
- triggering, 44–5
- trimethoprim, 434, 622
- trinitrobenzene sulfate (TNBS), 121
- 2,4,6-trinitrobenzenesulfonic acid (TNBS), 31–2, 166, 172, 347
- trinitrophenyl (TNP), 32
- trinitrophenyl-keyhole limpet hemocyanin (TNP-KLH), 121
- tripotassium dicitratobismuth, 428
- Tripterygium wilfordii* Hook.f., 695
- trophozoites, 107, 296, 646, 651–2
- tropomyosin, 557, 559
- Truelove and Witts severity index, 328, 418
 modified, 328
- Trypanozoma cruzi*, 141
- tryptase inhibitors, APC 2059, 429
- tuberculin skin testing (TST), 683–4, 709
- tuberculosis, 294–6, 371, 375, 383–4, 425, 478
 abdominal, 652
 and anti-TNF therapy, 683–4
 intestinal, 652–3, 711
 reactivation, 709
- tumor markers, 540
- tumor necrosis factor-like 1 (TL1A), 134
- tumor necrosis factors (TNFs), 27, 119
 biological effects of, 195
 monoclonal antibodies to, 424–5
 and postoperative recurrence, 504
 receptors, 130, 371
 systemic effects of, 197
 TNF α , 5–6, 25–8, 30, 33–5, 55, 82, 130, 183, 285, 369, 371, 382, 605
 and bone modeling, 666
 inhibitors, 371–7
 and malignancy, 384–5
 production, 372
 and tuberculosis, 383
- TNF β , 26
- tumor suppressor genes, 511–12
- turmeric, 405, 697
- turpentine, 197
- typhoid, 648
- tyrosine kinases, 88
- Tysabri, 678
see also natalizumab
- ubiquitin, 339
- ubiquitination, 86, 87

740 *Index*

- ulcerative colitis *see* colitis, ulcerative
- ulcers
 - anal, 491
 - aphthous, 232–3, 255, 296, 612
 - bear claw, 260
 - biopsies of, 247
 - configurations in CD, 237
 - drainage for, 3
 - flask-shaped, 296, 299
 - genital, 299
 - intestinal, 198
 - oral, 233, 299
 - perforating, 38
 - perianal, 297
 - rake, 612
 - skin, 42
 - solitary rectal (SRUS), 298
 - stellate, 260
- ultrasound, 259, 267–8
 - and fistula detection, 268
 - postoperative, 267–8
 - transabdominal, 267, 587
- undulin, 605
- ureter, 236
- urethritis, 648
- uric acid, 237
- ursodeoxycholic acid (UDCA), 258, 520, 533, 536–9
- Ussing chamber, 183
- utility scores, 679
- uveitis, 299, 553–4, 559–60

- vaccinations, and immunosuppression, 576
- VadinBE97, 95
- vagina, 235
 - fistulas to, 493–4
- vagotomy, 489
- vagus nerve, counter-inflammatory action of, 188
- valves of Kerckring, 256
- vancomycin, 428, 456, 623
 - and *C. difficile* diarrhea, 621, 625, 632–5, 633
- varicella, 384, 684
 - zoster virus (VZV), 680
- vasa recta, engorgement of, 270
- vascular adhesion protein (VAP-1), 533
- vascular cell adhesion molecule-1 (VCAM-1), 611–13
- vascular endothelial growth factor (VEGF), 172
- vasculature
 - of the gut, 610–11
 - role in chronic intestinal inflammation, 157–69
- vasculitides, 6, 237
- vasculitis, 297, 299
 - cutaneous, 565
- vasculotropin, 172
- vasoactive intestinal peptide (VIP), 184–5
- vasoconstriction, 167, 611
- vasoconstrictors, 157, 166
- vasodilation, 166, 611
- vegetables, 403
- venules, 611
 - high endothelial (HEVs), 159
- veres needle technique, 451
- Verrucomicrobia, 95
- vessels, colic, 446
- Veterans Health Administration, 310
- Vibrio*, 294
 - cholerae*, 108
 - parahaemolyticus*, 296
- Vienna classification, 4, 464
- villi
 - loss of, 183
 - lymphocyte-filled, 99
- vipomas, 603
- viruses, 296
 - infections by, 384
- visilizumab, 379, 426
- vitamin A, 171, 565
- vitamin B, 695
- vitamin B1, 410
- vitamin B6, 237, 410
- vitamin B12, 198, 230, 237, 293
 - deficiency of, 409–10, 563
- vitamin C, 405, 409–10
- vitamin D, 171, 541, 565, 667, 671–3
 - and cancer, 673
 - deficiency of, 410
- vitamin E, 405, 409, 565
- vitamin K, 565
- vomiting, 229
- von Willebrand factor, 164–5
- von Willebrand's disease, 165, 202
- VSL#3, 397–8, 429, 463
 - and postoperative recurrence, 503–4
- Waldeyer's fascia, 446
- Wegener's granulomatosis, 299, 532
- weight loss, 130, 195–6, 232
 - in CD, 229–30
 - and IL-18, 126
 - in pediatric patients, 591
 - and PSC, 258
- Wellcome Trust Case Control Consortium (WTCCC), 7, 17
- wheat grass juice, 695, 709
 - mode of action, 699
- WHO Mortality Database, 220
- whole genome association studies (WGAS), 18
- Wiskott–Aldrich syndrome, 136
 - protein (WASP), 36
- women
 - fertility and sexual function of, 568–9
 - medications during pregnancy, 572–7
 - and microscopic colitis, 601–2
- World Congress of Gastroenterology, 312
- Guidelines on IBD, 250, 312
- World Gastroenterology Organization, 312
- World Health Organization (WHO) densitometric classification, 672
- wormwood, 697

- yeasts, 94, 109, 280, 429, 636
- Yersinia*, 292, 294–6, 556, 648
 - enterocolitica*, 108, 296, 644, 648, 651
 - pseudotuberculosis*, 296
- yersiniosis, 652
- Yukui tang*, 695

- zidovudine, 659
- zileuton, 428
- zinc, 410
 - deficiency of, 563, 565, 593
- zoledronic acid, 671
- zonula, 97
- zoonoses, 644
- zymogens, 163